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I 
Zusammenfassung 
 
 Das Humane Immundefizienz-Virus 1 (HIV-1) rekrutiert Wirtszellproteine und  
-Signalwege für seinen eigenen Lebenszyklus und beeinträchtigt viele Funktionen 
von Immunzellen, darunter die Phagozytose von Pathogenen durch Makrophagen. 
Diese Schwächung der Immunabwehr verursacht das acquired immunodeficiency 
syndrome (AIDS). 
Der Zusammenbau von HIV-1 geschieht sowohl an der Plasmamembran als auch in 
endosomalen Kompartimenten und wird durch das Struktur-Polyprotein Gag kon-
trolliert, das auch für die Freisetzung virusähnlicher Partikel (VLPs) aus der Wirts-
zelle sorgt. Vorangegangene Studie haben gezeigt, dass durch hohe induzierte Cal-
ciumkonzentrationen im Zytoplasma die Anzahl an VLPs in endolysosomalen 
Kompartimenten steigt und die VLP-freisetzung drastisch zunimmt [1,2]. Der ver-
antwortliche Mechanismus ist jedoch bisher unbekannt.  
Die vorliegende Arbeit zeigt zunächst, dass Calciumausschüttung aus Lysosomen 
die Fusion von Endosomen und Lysosomen - und damit die Exozytose der in Lyso-
somen enthaltenen VLPs - auslöst. Dieser Prozess wird durch Synaptotagmin VII 
reguliert und verhindert den Abbau eines Teils der in späten Endosomen und Lyso-
somen eingschlossenen VLPs. 
Der zweite Teil dieser Arbeit beschreibt die Entwicklung eines nanobiotechnologi-
schen Systems zur Eliminierung von Env/Gag-VLPs (HIV-VLPs) mit Hilfe von Makro-
phagen. Dieses basiert auf Immunoliposomen, die HIV-VLPs über anti-Env-
Antikörper binden und von Makrophagen dank membranständigem Phosphatidylse-
rin (PS), einem apoptotischen Signal, phagozytiert werden. Die Lipososmen imitie-
ren apoptotische Zellen und induzieren ihre Internalisierung und die lysosomale 
Aufnahme von HIV-VLPs. Das System nutzt einen effizienten Internalisierungsweg, 
der während der HIV-1-Infektion nicht beeinträchtigt ist. 
Diese Ergebnisse bieten neue Einblicke in die intrazellulären Prozesse der HIV-1 
Freisetzung und präsentieren PS-Immunoliposomen als neuen potentiellen nano-
medizinischen Ansatz zur Virusbeseitigung und HIV-Antigenpräsentation. 
 
Schlagwörter: HIV-1, virusähnliche Partikel, Immunoliposomen, Phagozytose 
 
  
 
II 
Abstract 
 
 Human immunodeficiency virus 1 (HIV-1) hijacks proteins and signaling path-
ways of the host cell for its own life cycle, thereby impairing many functions of im-
mune cells, including pathogen-phagocytosis by macrophages. The overall weaken-
ing of immune functions eventually results in the development of acquired 
immunodeficiency syndrome (AIDS). 
HIV-1 assembly takes place at the plasma membrane as well as in endosomal com-
partments and is governed by the structural polyprotein Gag, which is also suffi-
cient for the release of virus-like particles (VLPs) from the host cell. It was shown 
that an induced high cytoplasmic calcium concentration increases the amount of 
VLPs in endo-lysosomal compartments and results in a dramatic enhancement of 
VLP release [1,2]. However, the mechanism by which calcium can promote the re-
lease of VLPs remains to be determined.  
The first part of this work shows that release of calcium from lysosomes causes 
fusion between endosomes and lysosomes as well as exocytosis of lysosome-
entrapped VLPs. This mechanism is regulated by Synaptotagmin VII and prevents 
degradation of a part of the late endosome- and lysosome-entrapped VLPs.  
The second part focuses on the development of a nanobiotechnological system for 
the clearance of Env/Gag-VLPs (HIV-VLPs) by macrophages. This system is based 
on immunoliposomes that (1) bind HIV-VLPs via anti-Env antibodies and (2) are 
phagocytosed by macrophages due to the presence of phosphatidylserine (PS), an 
apoptotic signal. Essentially, the PS-liposomes mimic apoptotic cells thereby induc-
ing internalization and lysosomal delivery of bound HIV-VLPs. These immunolipo-
somes exploit an efficient internalization pathway not impaired upon HIV-1 infec-
tion.  
The results of this thesis provide new insights into the intracellular pathways con-
trolling HIV-1 release and demonstrate that PS-immunoliposomes can represent a 
novel nanomedical approach for viral clearance and HIV antigen presentation. 
 
Keywords: HIV-1, Virus-like particles, Immunoliposomes, Phagocytosis  
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The UNAIDS Global Report of AIDS epidemic 2013 declares that about 35 million 
people were living with human immunodeficiency virus (HIV) in 2012. This repre-
sents an increase from previous years and is owed to the fact that more people are 
receiving the life-saving antiretroviral therapy. In 2012 there were two million new 
HIV infections globally, showing a 33% decline in the number of new infections in 
2001. The number of AIDS deaths is also declining with 1.6 millions AIDS deaths in 
2012, down from 2.3 million in 2005. Despite the decrease of HIV infections and 
AIDS deaths in the last years, HIV/AIDS has remained on the top of the major 
causes of death during the past decade.  
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1 INTRODUCTION 
 
 
1.1 The biology of HIV-1 
 
HIV is a single-stranded, positive-sense, enveloped RNA virus, which belongs to 
the genus Lentivirus, family Retroviridae. This virus has probably originated 
through the evolution of a simian immunodeficiency virus (SIV) in non-human pri-
mates in West-central Africa and subsequently has been transferred to humans in 
the early 20th century [3]. Two types of the virus, HIV-1 and HIV-2, have been 
characterized. HIV-1 is the virus that was initially discovered (Figure 1): it is more 
virulent, more infective and is the cause of the majority of HIV infections globally. 
HIV-2, on the contrary, shows a lower infectivity, poor capacity to be transmitted 
and is mostly confined to West Africa regions. The transmission of HIV takes place 
mostly through sexual intercourse, contacts with infected blood and breast milk. 
 
 
Figure 1. One of the first electron microscopy images of HIV-1 budding in lymphocytes. Elec-
tron microscopy image of a thin section of virus producing cord lymphocytes. The inset shows various 
stages of particles budding at the cell surface. Adapted from [4]. 
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1.1.1 Structure and genome 
 
Mature viruses are composed by a viral envelope and a matrix [5]. In the inte-
rior part is enclosed a capsid, which itself encloses two copies of the single-stranded 
RNA genome and several enzymes (Figure 2). In the HIV-1 genome, starting from 
the 5’-end, are found the group-specific antigen (gag), the polymerase (pol), and 
the envelope glycoprotein (env) genes (Figure 3). The gag gene encodes a polypro-
tein precursor, which can be identified as Pr55, based on its molecular weight, or as 
“Gag”, the structure-protein. Subsequently to the release of the newly produced 
virus, the Gag protein undergoes a maturation process, during which it becomes 
cleaved by the viral protease (PR) to the mature matrix protein (also known as MA 
or p17), capsid (CA or p24), nucleocapsid (NC or p7), and p6 (Figure 2) [5]. Two 
spacer peptides, p2 and p1, are also generated upon Gag processing. The pol gene 
encodes for different enzymes that are initially synthesized as part of a large poly-
protein precursor, Pol (or Pr160, or “GagPol precursor”), whose synthesis results 
from a rare frame-shifting event during Gag translation. The pol-encoded enzymes, 
PR, reverse transcriptase (RT), and integrase (IN), are cleaved from Pr160 by the 
viral PR. The envelope glycoproteins are also synthesized as a polyprotein precursor 
(i.e. gp160). Gp160 is processed by a cellular protease during Env trafficking to the 
cell surface. The processing of gp160 results in the generation of the surface glyco-
protein gp120 and the transmembrane glycoprotein gp41. Gp120 is responsible for 
the interaction with the CD4 receptor and the co-receptor(s), while gp41 anchors 
the gp120/gp41 complex in the membrane and performs the membrane fusion re-
action between viral and host lipid bilayers, during the virus entry process. HIV-1 
also encodes a number of regulatory and accessory proteins: Tat, Rev, Vpu, Vif, Vpr 
and Nef. Tat is critical for transcription of the viral genome, Rev plays a major role 
in the transport of viral RNAs from the nucleus to the cytoplasm. Vpu, Vif, Vpr and 
Nef have been recognized to be not uniformly required for virus replication, and 
therefore have been termed “accessory proteins”. 
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Figure 2. Schematic representation of HIV-1. From the outer part to the inner it can be found the 
spike proteins (Env), the lipid bilayer and the MA. Inside the particle the PR enzymes and the inner core 
of the virus, made by the CA proteins, can be found. Inside the core, there are the RT and IN enzymes 
and the viral RNA genome associated to NC residues. Adapted from [6]. 
 
 
 
Figure 3. Schematic representation of the HIV-1 genome. The relative locations of the HIV-1 open 
reading frames gag, pol, env, vif, vpr, vpu, nef, tat, and rev are indicated. The 5' and 3' long terminal 
regions (LTRs) are shown. The Ǔ indicates the position of the RNA packaging signal. The major Gag 
domains (MA, CA, NC, p6) and the Gag spacer peptides (p2 and p1) are shown under the gag gene. The 
site of Gag N-terminal myristylation is denoted as “myr”. Under the pol gene are indicated the PR, RT 
and IN coding regions. Sequences of the gp120 and gp41 Env glycoproteins are shown. Adapted from 
[5]. 
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1.1.2 Replication cycle 
 
 Once it has entered the host, HIV-1 can penetrate into specific target cells of 
the immune system and initiate its replication cycle (Figure 4): subsequent to the 
entry into the target cell, the viral RNA genome is first converted into a double-
stranded DNA and subsequently integrated into the cellular genome. After integra-
tion into the host DNA, the virus may be either immediately activated, resulting in 
transcription of viral RNA, production of viral proteins and assembly and release of 
new viral particles, or become latent, avoiding the detection by the immune sys-
tem. 
 
Entry mechanism 
HIV-1, as an enveloped virus, must fuse with the phospholipid bilayer of the host 
cell. This process, mediated by the spike-glycoprotein Env, leads to the disassembly 
of the viral core and the delivery of the viral genome to the cytoplasm and finally to 
the nucleus [7]. Fusion of HIV-1 with the target phospholipid bilayer mostly takes 
place at the plasma membrane (PM) [7]: a successful fusion between HIV-1 and 
target cell requires, initially, a high-affinity binding between gp120 and the T-
lymphocyte receptor CD4. This association triggers conformational changes in Env 
that enable subsequent interactions with the so-called “co-receptor”, which is a 
member of the seven-transmembrane chemokine-receptor family, usually CCR5 or 
CXCR4. This interaction, in turn, elicits more drastic changes in Env, releasing the 
fusogenic potential of gp41. Recently, it was shown that HIV-1 can also enter target 
cells via endocytosis [8]: after recognition and binding between Env and CD4/co-
receptor (CXCR4 or CCR5), the virus can be endocytosed and then fuse with the 
endosomal membrane releasing its viral core into the cytoplasm. Besides these en-
try pathways, also described as “cell-free entry pathways” [9], in several physiolog-
ically relevant cells types (T-cells, macrophages, and dendritic cells), HIV-1 was 
shown to be able to enter target cells through points of cell-cell contact, the so-
called “virological synapses” by analogy with similar structures–immunological syn-
apses that form between antigen-presenting cells and T-cells. An HIV-1 virological 
synapse is characterized by polarization of the actin cytoskeleton and by accumula-
tion of CD4, co-receptors, adhesion molecules, and tetraspanins, in addition to Gag 
and Env glycoproteins [10]. In macrophages, viral particles appear to assemble 
within an internal but surface-connected compartment [11]; in dendritic cells 
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(DCs), virus is thought to bind to the outer cell surface and then be taken into a 
similar compartment [12]. Such pre-assembled particles can subsequently move to 
the cell-cell junction on the way of synapse formation, allowing for efficient cell-cell 
transfer.   
 
Assembly and budding 
Following the integration into the host chromosome, the transcription of the viral 
RNAs, that ultimately encode the full complement of structural, regulatory, and ac-
cessory proteins used to direct virus replication, may start. The basal transcriptional 
activity from the provirus is initially very low: immediately after integration, only 
the host factors are responsible for the transcription process (e.g. RNA polymerase 
II, transcription factor IID, NF-kB). RNA synthesis is then greatly increased (by 
more than two logs) only when the transcriptional trans-activator protein Tat is pre-
sent [5]. The produced viral RNAs can be then either: I) unspliced, which function 
as the mRNAs for the Gag and Pol polyprotein precursors, and are packaged into 
progeny viruses as genomic RNA, or II) partially spliced mRNA, which are around 5 
kb in size and encode the Env, Vif, Vpu, and Vpr proteins, and III) small (1.7 to 2.0 
kb), multiply spliced mRNAs, which are translated into Rev, Tat, and Nef. Following 
the synthesis of the full complement of viral proteins, the assembly process takes 
place. The major player in virus assembly is the precursor polyprotein Gag [13]. 
This protein contains determinants that target it to the PM [14], where it specifically 
binds to phosphatidylinositol(4,5)-bisphosphate (PIP2) (Figure 6). Gag can also 
promote Gag-Gag interactions, encapsidate the viral RNA genome, associate with 
the viral Env glycoproteins, and finally stimulate budding from the cell [15,16]. The 
site of viral assembly has been shown to vary in respect of the infected cell: in T-
cell Gag traffics as monomers or lower-order oligomers to the PM, where it under-
goes higher-order multimerization and initiates particle assembly [17], while in 
macrophages or DCs Gag has been found to assemble in the lumen of late endo-
somes (LEs) or multivesicular bodies (MVBs) [18] (see further detail in the para-
graph "trafficking to the assembly site"- section 1.1.3). Gag and Pol are synthesized 
by free ribosomes in the cytoplasm, while Env synthesis takes place in the endo-
plasmic reticulum (ER) [19]. Pol is produced as the result of a rare frame-shifting 
event during Gag translation. The enzymes encoded by pol are then packaged into 
virus via their Gag domain, largely using the same Gag-Gag interactions that drive 
Gag assembly. The Env precursor protein gp160 is co-translationally inserted into 
the ER membrane, exposing its ectodomain into the lumen of the ER, where it 
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forms intramolecular disulfide bonds and undergoes oligomerization [19]. Subse-
quently, during transport though the Golgi, the gp120 domain is heavily glycosylat-
ed. The Env glycoprotein complexes that reach the cell surface can be then either 
rapidly internalized, through recognition by host cell machinery of an endocytosis 
motif in the gp41 cytoplasmic tail, or are incorporated into virus particles [20]. The 
final step in the process of virus assembly involves the pinching off, or budding, of 
the virus particle from the host cell PM. As many other retroviruses and different 
enveloped viruses, HIV-1 encodes specific sequences that promote particle release. 
These sequences are collectively referred to as “late domains” or “L-domains” to 
reflect their role late in virus assembly [21]. The L-domains are usually encoded in 
the Gag sequence; in the case of HIV-1, the L-domain is present in the p6 domain. 
Deletion of p6, or mutations within the highly conserved Pro-Thr/Ser-Ala-Pro motif 
located near the N-terminus of p6, can strongly impair particle release [22]. The L-
domain interacts with different host factors that play a fundamental role promoting 
the budding of viral particles. Specifically, the L-domain recruits the cellular endo-
somal-sorting complex required for transport-machinery (ESCRT), which normally 
assists budding and release of vesicles into the lumen of late endosomes [23]. The 
ESCRT machinery is known to comprise more than 25 proteins, organized into four 
complexes (ESCRT-0, -I, -II, and -III) that function sequentially along with several 
additional associated factors [24]. ESCRT-III and Vps4 (a protein required for the 
stripping of other ESCRT components) must be recruited to the bud neck to execute 
the final bud scission event and to release the ESCRT factors from the assemblage, 
for recycling back to the cytosolic pool [25]. The immature Gag shell, in which Gag 
molecules are radially arranged with their N-terminus in contact with the membrane 
and their C-terminus oriented toward the center of the virus, disassembles concom-
itant with particle release when the viral PR cleaves the Gag and GagPol polypro-
teins into their constituent proteins. 
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Figure 4. Schematic representation of the HIV-1 entry and release. On the left side are shown 
two entry mechanism: 1) endocytosis and subsequent fusion with the endosomal membrane and 2) 
direct fusion with the PM. Both entry mechanisms are followed by uncoating and release of the viral 
content, reverse transcription and HIV-DNA integration into the host genome. On the right side of the 
figure two exit mechanisms 1) direct assembly at the PM and 2) assembly in LEs/MVBs are shown. 
Mechanism 1: Gag traffics to the inner (cytoplasmic) leaflet of the PM where it initiates virus assembly 
and budding (typically observed in T-cells). Mechanism 2: Gag assembles on the cytoplasmic face of 
intracellular vesicles such as LE/MVBs, and the ensuing virus particles bud into the intraluminal space. 
The virus-harboring vesicles then traffic to and fuse with the PM, thereby resulting in the extracellular 
release of the virions. Adapted from [6]. 
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1.1.3 The structure-protein Gag 
 
Gag (Figure 5) is the major structural protein and the building block of HIV-1 
and comprises about 50% of the mass of a viral particle [26]. This protein, interact-
ing with different host factors, is necessary and sufficient for orchestrating particle 
assembly, since its expression alone, in suitable eukaryotic cells, leads to the pro-
duction of virus-like particles (VLPs) [27].  
 
 
Figure 5. Schematic representation of the Gag polypeptide. (A) Tertiary structure of the myristoy-
lated Gag. The Gag polypeptide, with helices (numbered from 1 to 19 starting from the N-terminal) and 
loops, is shown in blue with the respective atoms space-filling rendering. The regions responsible for the 
interaction of Gag with other viral proteins, as well as itself to form higher ordered structures, are high-
lighted in red. The position of the myristic acid is indicated by an arrow. (B) Schematic representation of 
the four major domain of Gag: MA, CA, NC, p6 and the two spacer-peptides (p2 and p1). N-terminal 
(NTD) and C-terminal (CTD) domains of CA are indicated highlighting their relevance in forming Gag-Gag 
interaction-interfaces. The specific amino acids involved in interactions between viral proteins (e.g. Env 
uptake, Vpr incorporation) and forming the two zinc-fingers are also indicated (orange). Adapted from 
[28]. 
 
The MA domain is composed by 128 amino acids and comprises five alpha helices 
and a three strand mixed beta sheets [28]. The N-terminus Gly-2 is post-
translationally myristoylated by covalent attachment of myristic acid by N-
myristyltransferase within the consensus sequence MGXXX(S/T)XX (see position of 
myrtistic acid in the Gag polypeptide in Figure 5). Myristoylation is critical for PM 
targeting and viral assembly [29]: the MA domain binds specifically to PIP2 in the 
inner leaflet of PM. This binding induces a conformational change in MA that expos-
es the N-terminus myristate moiety, which becomes inserted into the inner leaflet, 
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thereby stabilizing Gag-PM association. A PIP2 recognition motif sequesters the un-
saturated fatty acid of PIP2 into the same hydrophobic pocket from which the 
myristic acid group is displaced allowing interaction of the myristic acid group with 
the PM and forming a bi-directional lipid anchor (Figure 6) [30]. The MA domain is 
also involved in interaction with the cytoplasmic tail of the Env gp41 protein to aid 
incorporation of Env into the viral particles [19]. Within the mature virus, the CA 
domains (231 amino acids) form the structural core, while CA–CA interactions are 
essential for the formation of the immature particles and any effector that can in-
terfere with this process has a severe effect on viral replication. The proline-rich 
loop between helix 9 and 10 is a target for an innate immune factor, the tripartite 
motif-containing motif 5-alpha (TRIM5Į) [31], which interferes with the early stag-
es of viral uncoating during replication by targeting incoming virions to the pro-
teasome. TRIM5Į is a multimeric protein and forms hexameric lattices when stimu-
lated by the presence of a CA lattice. HIV-1 overcomes the binding of TRIM5Į by 
binding a molecule of cyclophilin A, a prolyl-peptidyl isomerase, to the same target 
site [32]. The NC region of Gag is constituted by 55 amino acids that form two zinc 
fingers separated by a functionally important basic domain. This region has two 
distinct roles during the assembly and maturation of the virus particle: I) to fulfill a 
major structural role within Gag–Gag interactions by forming the immature viral 
particle; and II) to play a role in nucleic acid recognition and interaction during viral 
replication [28]. The ALG-2-interacting protein X (ALIX), an ESCRT-associated pro-
tein that promotes viral budding, binds to both NC as well as p6 [33]. At the C-
terminus of Gag the p6 domain is located, made up of a 52 amino acids forming 
two helices. Two functional regions have been mapped to the p6 domain: an N-
terminal PTAP motif, which represents the late-domain and a C-terminal LXXLF se-
quence, which participates in the incorporation of Vpr into particles [34]. PTAP 
binds to the cellular tumor susceptibility gene 101 (Tsg101 or ESCRT-I), a protein 
involved in vacuolar cell sorting, which plays a fundamental role in the release of 
VLPs [35].   
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Figure 6. HIV-Gag association with PIP2 at the plasma membrane. The N-terminal myristic acid 
moiety of MA is depicted in its sequestered conformation. PIP2 embedded in the inner leaflet of the 
plasma membrane lipid bilayer is shown with its 1’ (orange) and 2’ (yellow) acyl-chains in the lipid bi-
layer. The arrows indicate the binding between MA and PIP2, which leads to the flipping out of the 
myristate moiety into an exposed conformation and its subsequent insertion into the lipid bilayer. 
Adapted from [6]. 
 
Trafficking to the assembly site 
After its synthesis in the cytosol, Gag can traffic as monomer or lower-order oli-
gomers to membranes, where it undergoes higher-order multimerization and initi-
ates particle assembly. Interestingly, in vitro soluble Gag exists in monomer-dimer, 
monomer-trimer equilibrium, or can even assemble into a small sphere [36], sug-
gesting that Gag may possess an intrinsic capability to build up into particles with a 
spherical shape. Gag binding to cell membranes (mostly PM) has been observed to 
take place already within 5–10 min post-synthesis [37]. The observations that cho-
lesterol depletion diminishes PM binding of Gag, disrupts higher-order Gag multi-
merization and impairs virus production, together with other biochemical and mi-
croscopic data, implicate Gag association with lipid rafts [38]. Lipid rafts, also 
referred to as “membrane-rafts”, are highly dynamic membrane microdomains that 
are rich in cholesterol and sphingolipids, display lateral heterogeneous protein dis-
tribution, and compartmentalize cellular processes [39]. The Env glycoproteins 
were also shown to be raft-associated, at least in part due to their association with 
Gag, and specifically the gp41 cytoplasmic tail has been reported to contain the 
determinants for Env association with rafts [40]. However, for a successful viral 
assembly at the PM, it is also required that all viral components traverse the cyto-
plasmic space and precisely target to the PM. In fact, it has been shown that in cells 
physiologically relevant for HIV-1 infection, like macrophages and T-lymphocytes, 
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but also in epithelial cells, Gag and, in some cases, VLPs are localized into intracel-
lular compartments enriched in late endosomal and lysosomal markers [2,41]. A 
schematic representation of the suggested pathway for viral assembly is reported in 
Figure 7. 
 
 
Figure 7. Potential involvement of endosomal trafficking pathways in Gag targeting. Potential 
Gag trafficking routes. Gag may be either directly targeted to the PM (pathway 1) or transported to the 
PM through endosomal trafficking routes (pathway 2). Along the latter pathway, Gag may form virus 
particles inside the endosomal lumen and later get released by fusion of endosomes with the PM (path-
way 3). However, the interpretation of Gag localization data is complicated because virus particles accu-
mulated in endosomes may have been formed at the PM and internalized before being released to the 
extracellular space (pathway 4). Adapted from [30]. 
 
This suggests that nascent Gag may be at least in part targeted to endosomal 
membranes for assembly, and the resultant particles may bud into the lumen of 
late endosomes/multivesicular bodies from which they exit the cell by usurping cel-
lular processes such as the exosome release pathway [42]. Moreover, as also previ-
ously mentioned, it is well established that HIV-1 budding requires the activity of 
ESCRT proteins, which usually are designate to facilitate the budding of vesicles 
into the endosomal lumen [33]. Among the many intracellular factors known to 
facilitate the trafficking of Gag to the assembly site(s), intracellular calcium levels 
and activation of the phospholipase C (PLC) pathway have been hypothesized to 
modulate Gag trafficking [43]. In a study on HIV-1 particle production it was 
demonstrated that induction of a transient rise in the cytosolic calcium concentra-
tion results in a dramatic rise in viral particle release, suggesting that calcium might 
represent a limiting factor in late-stage replication [2,44]. In parallel in another 
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work, it was demonstrated that activation of PLC and modulation of inositol(1,4,5)-
triphosphate receptor (IP3R) function, i.e., recruitment of IP3R to the cell periphery 
and gating of intracellular calcium stores, influence Gag accumulation at the PM and 
virus release [1]. Even if the exact role of the activated IP3R and how elevated cal-
cium enhances Gag accumulation at the PM remains to be determined, a prelimi-
nary model of functions has been proposed: recruitment of IP3R machinery to the 
cell periphery and release of calcium may function to increase the portion of PM 
PIP2 available for interaction with Gag. Considering that PIP2 does not have a natu-
ral inclination for clustering, due to the energy barrier posed by repulsion of the 
large polar head groups when they are in proximity, calcium might reduce this bar-
rier and induce PIP2 clustering in lipid monolayers [45].  
 
Virus-like particles: formation and release 
VLPs are replication as well as infection incompetent, since they lack regulatory 
proteins as well as infectious genetic material. This property has allowed them to be 
used and studied in different contexts [46,47]. In the context of a mammalian ex-
pression vector, VLP formation requires (at least) the presence Gag and specifically 
of the N-terminal domain of CA (amino acids 133 to 277) for assembly, budding 
and release in human embryonic kidney 293T (HEK-293T) cells [22,48] (see VLPs 
formation pathway in Figure 8A-C). Co-expression of Gag and Env results in the 
formation and release of VLPs bearing also the spike glycoproteins (see VLPs for-
mation pathway in Figure 8F). Besides targeting of membrane binding and virus 
assembly, MA also influences Env glycoprotein incorporation in the nascent particle. 
An appealing model invokes, that entrapment of Env into virions is strictly regulated 
by an interaction between sequences within the long cytoplasmic tail of gp41 and 
holes present in the lattice-like matrix structure formed upon MA trimerisation [47]. 
VLPs destined for biochemical and immunological analysis can be easily purified by 
ultracentrifugation through sucrose gradients resulting in particles with a purity of 
greater than 80%. Obtained 100–120 nm VLPs include approximately 1500–1800 
Gag monomers and resemble morphologically and antigenically native virions [36]. 
The fact that these VLPs are quite stable and can be manufactured in sufficient 
quantities makes them an attractive candidate as subunits for a vaccine. Recently, 
Gag- based VLPs have been used with success as a tool for vaccination against hu-
man papillomavirus [49], and, concerning HIV-1, the Gag-based VLP model has 
been employed to deliver additional antigenic structures, such as specific individual 
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epitopes or whole proteins, with induction of the immune response [47,50]. 
 
 
Figure 8. Schematic representation of the HIV Gag polyprotein and particle formation. (A) The 
Gag polyprotein, consisting of the p17 matrix (MA), the p24 capsid (CA), the p7 nucleocapside (NC) and 
the p6 linker protein, includes all information to (B) be targeted to the inner leaflet of the membrane of 
the producer cell and (C) bud in form of enveloped virus-like particles (VLP). (D and E) Electron micro-
graphs of VLPs budding from insect cells after infection with Gag-recombinant baculoviruses. (F) The Env 
glycoprotein, which consists of the transmembrane domain gp41 and the spike domain gp120, is insert-
ed in the VLP membrane if co-expressed with Gag. Adapted from [47]. 
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1.2 HIV-1 immunopathogenesis 
 
1.2.1 Infection and immune response 
 
Transmission  
Most HIV-1 infections occur by sexual exposure through the genital tract or rec-
tal mucosa. It is still uncertain whether HIV-1 is transmitted as a free or a cell-
bound virus, but SIV can be transmitted in either form [9]. The exact mechanism 
by which HIV-1 passes through the genital mucosal epithelium is still not clear. Dif-
fusion of HIV-1 across the vaginal mucosa is slowed by genital mucus. It is pre-
sumable that virus crosses the mucosal epithelium barrier by transcytosis or by 
making direct contact with intraepithelial dendritic cells (DCs). Given that, multiple 
sexual exposures are usually needed for infection to occur. The crossing of the epi-
thelial cell barrier by the virus is probably a rare event, although it is more common 
if the genital mucosa is damaged by physical trauma or coexisting genital infections 
[9].  
 
Phases of infection 
A period of about 10 days, following transmission of the virus, is commonly 
known as the eclipse phase. It corresponds to the period of time before viral RNA 
becomes detectable in the plasma (Figure 9). It has been suggested that the estab-
lished infection probably arises from a single focus of infected mucosal CD4+ T-cells 
[51]. Infectious molecular clones derived from these primary founder viruses, the 
quasispecies1, could infect CD4+ T-cells with greater efficiency than they could infect 
macrophages. A second species (i.e. “unit”) of the virus may arise later in the infec-
tion, and can infect equally different immune cell types (e.g. monocytes, macro-
phages). At the end of the eclipse phase, virus and/or virus-infected cells reach the 
draining lymph node, where they meet activated CD4+ CCR5+ T-cells, which are 
targets for further infection [9]. The virus can then replicate rapidly and spreads 
throughout the body to other lymphoid tissues (e.g. gut-associated lymphoid tis-
sue), where a high number of activated CD4+ and CCR5+ memory T-cells are pre-
sent [52].  
                                          
1 A distribution of non-identical but closely related viral genomes. The entire distribution forms an orga-
nized cooperative structure, which acts like (quasi) a single unit (species). 
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Figure 9. Fundamental events in acute HIV-1 infection. Following HIV-1infection, the virus first 
replicates locally in the mucosa and is then transported to draining lymphnodes, where further amplifica-
tion occurs.  This initial phase of infection, until systemic viral dissemination starts, constitutes the 
eclipse phase. The time when virus is first detected in the blood is referred to as t0; after this there is an 
exponential increase in plasma viraemia to a peak 21–28 days after infection. By this time, significant 
depletion of mucosal CD4+ T-cells has already occurred. Around the time of peak viraemia, patients may 
become symptomatic and reservoirs of latent virus are established in cells that have a slower rate of 
decay than CD4+ T-cells. The ‘window of opportunity’ between transmission and peak viraemia, prior to 
massive CD4+ T-cell destruction and the establishment of viral reservoirs, is the narrow but crucial peri-
od in which an HIV-1 vaccine must control viral replication, prevent extensive CD4+ T-cell depletion and 
curb generalized immune activation. Adapted from [9]. 
 
At this time point, a large number (about 60%) of uninfected CD4+ T-cells become 
activated and die by apoptosis, resulting in the release of apoptotic particles that 
can suppress immune function [53]. Consequently, in the first three weeks of HIV-1 
infection about 80% of CD4+ T-cells, located in the gut-associated lymphoid tissues, 
can be depleted. During viral replication, the plasma viraemia2 increases exponen-
tially to reach a peak (more than a million RNA copies per ml of blood). This corre-
sponds to a strong decrease of the CD4+ T-cell number, which will subsequently 
return to near normal levels in the blood but not in the gut-associated lymphoid 
tissues [54]. After the peak viraemia, the viral load decreases over about 20 weeks 
to reach a more stable level, known as the viral set point (Figure 9). Interestingly, 
                                          
2 From the word "virus" together with the old-greek word for blood (haima), viraemia is the medical 
condition, which defines the entry of viruses in the bloodstream and their consequent access to the rest 
of the body. 
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during this initial phase, the peak viraemia, the amino acid sequence of the virus 
does not undergo relevant changes. Virus diversification occurs during the period of 
decrease in viral load [55,56]. Different HIV-1 infected cells can differently respond 
to infection in terms of half-life: for most infected memory T-cells, the half-life is 
less than a day [57], while for macrophages, that can maintain latent pools of HIV-
1 for months, the rate of decay is much slower [58].  
 
Immune cells activation  
Immune activation is associated with early and extensive apoptosis of B- and T- 
cells, leading to the release of apoptotic microparticles into the blood, and in-
creased expression of tumor necrosis factor (TNF)-related apoptosis-inducing lig-
ands, which kill bystander cells and are immunosuppressive [59]. The causes of 
HIV-1-associated immune activation established in early infection are not clearly 
defined [9]. Multiple related events probably contribute to such activation, including 
direct viral infection of immune cells, pro-inflammatory cytokine production by in-
nate cells (which drives both direct and bystander activation of other immune cells), 
translocation of microbial products into the blood through damaged intestinal epi-
thelium [60], loss of virally infected regulatory T-cells and chronic mycobacterial 
and viral co-infections. 
 
1.2.2 Infection of macrophages 
 
Macrophages are terminally differentiated, non-dividing cells, derived from cir-
culating monocytes [61]. They represent a distinct population of phagocytes that 
are found under different names in various tissues (e.g. microglia in the brain, al-
veolar macrophages in the lung, or Kupffer cells in the liver) and are involved in 
various functions (e.g. bone remodeling, muscle regeneration) acting in both innate 
and adaptive immunity (Figure 10). Macrophages phagocyte cellular debris and 
pathogens, therefore possess a very active endo-lysosomal system, and almost no 
intermediate compartments [11]. This suggests that internalized materials are very 
rapidly targeted to acidic compartments (i.e. LYs). Macrophages also act as profes-
sional antigen presenting cells (APC), triggering antibody responses by the presen-
tation of pathogen derived peptides via the major-histocompatibility complex II 
(MHCII) pathway to CD4+ T-cells and activating CD8+ cytotoxic T-cells (CTL) by 
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cross-presentation of HIV-1 antigens [11]. Nevertheless, even if macrophages are 
very resistant to the cytopathic effects of HIV-1 replication (compared to activated 
CD4+ T-cells) their ability to infiltrate almost all organs (including the brain), and 
their presence in many different tissues can critically contribute to the spread of 
HIV-1 within the infected body [62]. In fact, it has been shown that macrophages 
infection is responsible for many AIDS-associated neuronal disorders [63]. Fur-
thermore, macrophages has been implicated in mother-to child transmission due to 
breast feeding [62].   
 
 
Figure 10. Schematic representation of the macrophages lineage. Monocytes originate in the 
bone marrow from a common hematopoietic stem cell (HSC). They undergo differentiation steps during 
which they commit to the myeloid and then to a monocyte lineage. In response to macrophage colony-
stimulating factor, they divide and differentiate into monoblasts and then pro-monocytes before becom-
ing monocytes, which exit the bone marrow and enter the blood stream. Human monocytes can also be 
divided into inflammatory and resident populations. Monocytes migrate to different tissues, where they 
replenish tissue-specific macrophages. The following abbreviations are used: central nervous system 
(CNS); granulocyte/macrophage colony-forming unit (GM-CFU); macrophage colony-forming unit (M-
CFU); connective tissue (CT). Adapted from [61]. 
 
Potential active role of macrophages against HIV-1 infection 
Non-infected macrophages can fulfill a potential relevant role against HIV-1 
[64].  Macrophages can provide for an efficient and rapid phagocytosis of the virus 
with consequent presentation of viral-derived peptides via MHCII to CD4+ T-cells. A 
further cross presentation of antigens via MHCI complexes can optimize an anti-
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HIV-1 CTL response [11]. Furthermore, a variety of host-cell factors in macrophag-
es (but also in some other reservoir cells) able to counteract the HIV-1 life cycle at 
different steps have been described and are now collectively called HIV-1 restriction 
factors (RFs) [18]. These RFs are usually induced by interferon-Į and exert potent 
antiviral activity in cell culture. However, it must be taken into account that coevo-
lution of virus and host had as a consequence the development of a repertoire of 
versatile viral accessory proteins able to counteract the activity of many RFs [63]. 
For example: one well known RF of macrophages is the SAM domain and HD do-
main-containing protein 1 (SAMHD1)3, which is a cellular enzyme that exhibits 
phosphohydrolase activity converting nucleotide triphosphates to a nucleoside and 
triphosphate. SAMHD1 can deplete the pool of nucleotides available to a reverse 
transcriptase for viral cDNA synthesis and thus prevents viral replication. Neverthe-
less, degradation of SAMHD1 induced by Vpx (a virion-associated protein expressed 
by HIV-2, similar in structure to Vpr) is sufficiently rapid to allow reverse transcrip-
tion of the viral RNA [65].  On the contrary, Tetherin, another well-known RF, which 
causes retention of fully formed virions on infected cell surfaces, is not antagonized 
by any viral protein in infected macrophages. Due to its high expression in macro-
phages, Tetherin can produce a strong inhibition of viral release in these cells com-
pared to the viral production efficiency in CD4+ T-cells, where the viral protein Vpu 
counteracts the inhibition activity of Tetherin allowing an efficient viral release from 
the PM [11].  
  
Impairment of macrophage immune functions upon HIV-1 infection: a 
focus on FcǄ-receptor-mediated phagocytosis 
HIV-1 infection of macrophages results in the impairment of a many of their 
immune functions (e.g. chemotaxis, phagocytosis, intracellular pathogens killing, 
cytokine production [66,67]). These defects contribute to the pathogenesis of AIDS 
by allowing reactivation and development of opportunistic infections [68]. The HIV-
1-encoded proteins Nef, Vif, Vpr, and Rev have been shown to affect a number of 
signaling pathways via interactions with cytoskeletal and cytoplasmic proteins [63]. 
Specifically, it was shown that the activity of some kinases (e.g. the Src and p21-
activated kinases) involved in antibody-mediated phagocytosis processes, such as 
the FcǄ receptor (FcǄR)-mediated phagocytosis, are strongly impaired upon HIV-1 
infection [68-70]. This kind of phagocytosis refers to the binding of the FcǄR to a 
                                          
3 Sterile Alpha Motif (SAM) and Histidine Aspartic (HD) domain-containing protein 1. 
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part of an antibody known as the Fc4_region [71]. Fc receptors are the receptors for 
the constant region of IgG (FcǄRI, FcǄRII, and FcǄRIII). They bind to antibodies 
that are attached to infected cells or invading pathogens. Their activity stimulates 
phagocytic or cytotoxic cells to destroy microbes, or infected cells by antibody-
mediated phagocytosis or antibody-dependent cell-mediated cytotoxicity (ADCC) 
[72]. Those that bind the class of antibody IgG are called Fc-gamma (Ǆ) receptors. 
Peripheral blood monocytes express mainly the high-affinity FcǄRI (CD64) and a 
low-affinity FcǄRII, whereas macrophages also express FcǄRIIIA (CD16A). Previous 
studies have shown that Syk activation in FcǄR-mediated phagocytosis is an abso-
lute requirement [73]. Activation of Syk results in cytoskeletal rearrangements 
needed for phagocytosis of the opsonized particles (Figure 11). A previous study 
has shown that defective phagocytosis by HIV-1-infected macrophages is due, at 
least in part, to decreased expression of the FcǄR-signaling subunit of the FcǄR, 
which leads to specific signaling defects downstream of FcǄRs [68]. 
 
 
Figure 11. Signaling pathway triggered by activating FcǄR. Crosslinking of activating Fc receptors 
for IgG (FcǄRs) by immune complexes induces the phosphorylation of receptor-associated Ǆ-chains by 
the SRC kinase (not indicated). This generates docking sites for SYK, which in turn activates a number of 
other signal-transduction molecules such as phosphoinositide 3-kinase (PI3K). The generation of phos-
phatidylinositol-3,4,5-trisphosphate (InsP3) recruits phospholipase CǄ (PLCǄ), which leads to activation 
of downstream kinases and the release of calcium from the endoplasmic reticulum (ER). Adapted from 
[71]. 
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 Apoptotic cell phagocytosis by macrophages during HIV-1 infection 
 Phagocytes, and specifically macrophages, are required to continually sense 
the extracellular environment [61]. A set of distinct cell surface receptors is re-
quired for recognizing and responding to infectious and non-infectious injuries. The 
FcǄR-mediated phagocytosis is only one of the internalization ways active in macro-
phages [74]. Phagocytic cells, and macrophages in first line, also have the task of 
sensing the presence of dead entities, binding to specific molecules expressed on 
the outer surface of apoptotic cells [75]. Phosphatidylserine (PS) (see chemical 
structure in the Appendix) represents one of the most important apoptotic signals 
for engulfment of apoptotic cells by macrophages [74,75]. Clearance of apoptotic 
cells is necessary for tissue development, homeostasis and resolution of inflamma-
tion [75,76]. The uptake of apoptotic cells is initiated by an ‘eat-me’ signal, such as 
PS, on the cell surface and phagocytes recognize this signal by using specific recep-
tors [76]. Several classes of receptors have been implicated in the recognition of 
apoptotic cells, by means of direct binding to the exposed PS, including brain-
specific angiogenesis inhibitor 1, T-cell immunoglobulin and mucin domains-
containing protein 4 and stabilin-2, or indirect binding through bridging molecules 
(milk fat globule-EGF factor 8 protein, growth arrest-specific 6 [77]). The engage-
ment of the PS receptors initiates signaling events within the phagocytes that lead 
to activation of specific intracellular signaling which ends to cytoskeletal reorganiza-
tion of the phagocyte membrane, to allow corpse internalization. PS is a glycer-
ophospholipid present in the membranes of all eukaryotic cells. Like the majority of 
glycerophospholipids, PS has a glycerol backbone esterified on the sn-1 and sn-2 
carbons of the glycerol moiety with 2 fatty acyl chains of variable length and satu-
ration, and a phosphate group on sn-3 (see chemical structure in the Appendix) 
[78]. The distinguishing feature of PS is the attachment of a serine to the phos-
phate; the resulting head-group provides PS a net negative charge. While PS is 
present in all cells, it is a comparatively minor constituent of their membranes, 
comprising 3–10% of the total lipids [78]. However, this low relative abundance of 
PS belies its importance within the cell. The best-studied roles of PS involve signal-
ing, not within the intracellular environment, but in an extracellular context such as 
during apoptosis and during blood clotting. Like most lipids, PS is not evenly dis-
tributed throughout all cellular membranes, nor is it always equally distributed be-
tween leaflets of a membrane bilayer [75]. In healthy cells PM PS is exclusively on 
the inner (cytoplasmic) leaflet due to the action of ATP-dependent aminophospho-
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lipid flippases [78]. When cells undergo apoptosis (the regulated cell death) PS ap-
pears on the outside leaflet, signaling phagocytic cells to engulf the dying cell 
(Figure 12). The CD91 receptor, also called low density lipoprotein receptor-related 
protein 1 (LRP1), binds to ǃ2-glycoproteins, which in turn has been reported to di-
rectly interact with PS of apoptotic bodies [79]. The LRP1 was shown to be in-
creased on the surface of HIV-1 infected macrophages [80]. This suggests that, 
although most of immune functions of the macrophages are impaired due to HIV-1 
infection, some phagocytic ways, e.g. PS-mediated phagocytosis, might still be ac-
tive. 
 
 
Figure 12. Schematic representation of the re-distribution of PS in the lipid bilayer during 
apoptosis. PS (blue) is initially asymmetrically localized in the lipid bilayer. During apoptosis, PS re-
distributes symmetrically in the lipid bilayer, flipping to the outer leaflet of the PM. 
 
1.2.3 Therapeutic approach against HIV-1 
 
 Development of many antiretroviral drugs has made HIV-1 infection a treata-
ble chronic disease [81]. Antiretroviral therapy (ART) includes use of different drug 
classes, for instance: nucleoside (or non-nucleoside) reverse transcriptase inhibi-
tors; protease inhibitors; integrase inhibitors; fusion and entry inhibitors [82]. Cur-
rent recommendations for initial therapy for HIV-1 infection include the use of the 
so-called combined antiretroviral therapy (cART), which corresponds to a combina-
tion of three antiretrovirals from at least two drug classes. cART is effective in de-
creasing HIV-1 RNA level below the limit of detection (50 copies/mL) and has led to 
significant reductions in HIV-related morbidity and mortality and is a highly cost-
effective medical intervention [83]. In general, initiation of cART soon after infec-
tion offers near normal quality of life and lifespan: early cART is in fact associated 
with a reduced latent viral reservoir, reduced viral DNA, and normalization of some 
immune markers, leading to prevention of the various complications that define 
AIDS [83]. However, cART does not fully restore health, and lifelong treatment is 
Apoptosis
PS flipping to the outer leaflet of the PM
PS is asymmetrically localized in the inner leaflet of the PM
Inner leaflet
Outer leaflet
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necessary to manage patient illness because cART neither eradicates infected cells 
from reservoirs nor reconstitutes HIV-1-specific immunity that could kill infected 
cells. Furthermore, findings from studies undertaken in high-income countries show 
that HIV-1-infected adults who have durable treatment-mediated suppression of 
HIV replication are at risk for developing several non-AIDS disorders, including car-
diovascular disease, cancer, kidney disease, liver disease, osteopenia or osteoporo-
sis, and neurocognitive disease [84]. Beside the compelling need of an HIV-1 vac-
cine, the request for new and alternative treatment approaches is still increasing 
[85]. Some suggestions to this end, might come from the research in nanotechnol-
ogy [86].  
 
Nanotechnology in the treatment of HIV-1 
Toward the cure of HIV-1, different nanomedicine classes have been developed 
with different disease-modifying properties [87]. Application of nanotechnology to 
the delivery of antiretroviral drugs might represent an important tool in the cure of 
HIV-1, for example modifying tissue-distribution of drugs that could be targeted to 
viral reservoirs and by increasing their half-lives. To this aim, copolymer micelles 
incorporating the non-nucleoside revers transcriptase inhibitor efavirenz into their 
core were developed [88]. Furthermore, nanomedicine formulation might help in 
the targeting of antiretroviral drugs to specific cell types (e.g. DCs, Langerhans 
cells) or organs (e.g. lymphoid organs). Lipid-nanoparticle loaded with the protein 
kinase C activator, bryostatin-2 [89] and pH-dependent nanoparticle containing the 
protease inhibitor indinavir [90] were produced to target antiretroviral drugs to DCs 
and Lymphoid organs, respectively. Some nanomedical formulations were also de-
signed as preventive therapy, as promising strategy to prevent vaginal and rectal 
HIV-1 transmission (e.g. the vaginal gel containing the nucleoside reverse tran-
scriptase inhibitor tenofovir [91]). Moreover, to increase the epithelial penetration 
of antiretroviral-based microbicides, specific mucoadhesive and non-mucoadhesive 
nanomedicine formulations were also investigated [92]. Nanotechnology research 
was also directed to the development of immunotherapeutic nanocomplexes, mul-
timodular vaccine candidates that may provide high therapeutic effects in compari-
son to all previous approaches [87]. Many biological phenomena, such as immune 
recognition and passage across biological barriers, are governed by size considera-
tions. The physical size of nanocomplexes is usually over 50 nm, which is the ap-
proximate threshold of immune recognition [86]. Soluble antigens, with a diameter 
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smaller than 50 nm, are generally not recognized by the immune system and are 
not immunogenic. In fact, since nature developed an effective and specific immune 
surveillance against viruses, which takes in consideration also the size of the anti-
gens, immunotherapeutic nanomedicines must correspond to the size range of vi-
ruses. Consequently, the body would consider nanomedicine as a harmful virus that 
needs to be eliminated. DermaVir is the first nanomedicine developed for the 
treatment of HIV-1 and AIDS that has demonstrated encouraging Phase II clinical 
safety, immunogenicity, and efficacy results [87]. DermaVir features three ele-
ments: the first is the active pharmaceutical ingredient, which is a pDNA that ex-
presses 15 HIV-1 proteins. These proteins self assemble to replication-, reverse 
transcription- and integration-defective complex VLPs. The creation of such VLPs 
supports the presentation of the highest number of HIV-1 epitopes and might in-
duce HIV-1 specific T-cell responses. The second is a mannosylated polyethyl-
enimine “envelope”, which contains and delivers pDNA to DCs and achieve effective 
protein expression the pDNA. The third is the formed nanoparticle of 70-300 nm in 
a buffered solution.  
 
Liposomes as therapeutic tool against HIV-1 
Liposomes are lipid vesicles with an aqueous core used to encapsulate hydro-
philic drugs whereas hydrophobic and amphiphilic drugs can be solubilized within 
the phospholipid bilayers. Liposomes and several other nanocarriers are readily op-
sonized by plasma proteins, phagocytosed by macrophages and localize to cells of 
the reticuloendothelial system (RES). It has been shown how hydrophilic drugs en-
capsulated in liposomes can localize in organs rich in macrophages, such as liver, 
spleen and lungs [93,94]. Specifically, in one study it was shown how liposomes 
could be used to deliver the nucleoside reverse transcriptase inhibitor azidothymi-
dine (AZT) preferentially to the RES, sparing the bone marrow from this drug and 
thereby reducing bone marrow toxicity [95]. Furthermore, the surface of liposomes 
may be modified to increase their targeting specificity: for instance, cells of the RES 
bear galactose and lectin receptors [96]. Liposomes bearing galactose and mannose 
residues on their outer surface can specifically target these receptors, and have 
been used to direct, for example, the nucleoside reverse transcriptase inhibitor 
stavudine to the RES [86]. Formulation of antibodies-decorated liposomes (i.e. im-
munoliposomes) have the targeting specificity of antibodies on their surface e.g., 
anti-HLA-DR monoclonal antibodies which can target follicular dendritic cells, B-cells 
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and macrophages. Liposomes may also be decorated with recombinant soluble CD4 
molecules [97], or antibodies able to target gp120 on HIV-1 infected cells [98]. 
 
1.3 Aim of the work 
 
Approximately three decades ago, HIV was found to be the cause of AIDS [99]. 
Since their discovery, HIV-1 and the less infective HIV-2 are responsible for more 
than 25 million deaths worldwide, making HIV one of the insurmountable problems 
of the 21st century [100]. Scientific research on HIV-1 still has to respond to various 
open questions about the biology of viral assembly and the lack of immune re-
sponse against the infection [101]. This work will raise both these issues: first 
(point 1), to study the role of intracellular calcium for the release of viral particles, 
and second (point 2) the development of a nanotechnological strategy able to elicit 
clearance of viral particles circumventing the lack of immune response during HIV-1 
infection. 
1) HIV-1 can follow more than one assembly pathway and partially adapt its 
own life cycle, exploiting different components of the cellular machinery in 
regard to the type of infected cell: in macrophages and DCs, HIV-1 assembly 
takes place mostly in LEs/MVBs where it can remain inactive for several 
months after infection [18], while in T-cells, HIV-1 buds predominantly from 
the PM [17].  
The use of different investigation methods and different cell lines as model 
systems for the study of the biology of HIV-1 assembly and replication has 
led to sometimes-contradictory observations. Several studies have shown 
the presence of VLPs in late endosomes and as well in lysosomal compart-
ments [2,23]. Nevertheless, the fate of such late endosomes/lysosomes 
(LEs/LYs) entrapped VLPs is still a matter of debate. However, increased in-
tracellular calcium concentrations were shown to enhance the release of 
VLPs [2,44]. This process has been proposed to be caused by fusion events 
between vesicles of the endo-lysosomal system containing VLPs [2]. This 
suggests a possible role of the LEs/LYs calcium-mediated fusion machinery 
and LYs exocytosis, which are common mechanism shared by all cell types 
[102], in the release of VLPs and their rescue from lysosomal degradation. 
The aim of the first part of this work was to investigate the role of intracellu-
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lar calcium and the LEs/LYs machinery in the release of VLPs.  
2) Although the advent of cART, antiretroviral therapy is associated with a high 
number of disadvantages (e.g. emergence of drug resistant viral strains, se-
rious adverse effects and inability to eradicate HIV-1 from reservoirs [82]). 
In this scenario, nanotechnology, which can bring together physicochemical 
and biological properties of different therapeutic approaches, has a vast po-
tential to advance the treatment of HIV/AIDS. In this work, immunolipo-
somes are presented that can bind Env/Gag virus-like particles (HIV-VLPs) 
while being specifically phagocytosed by macrophages, thus allowing the co-
internalization of HIV-VLPs. These liposomes are decorated with anti-Env an-
tibodies and contain PS. PS mediates liposome internalization by macro-
phages via a mechanism not impaired by HIV-1.   Hence, PS- liposomes 
mimic apoptotic cells and are internalized into the macrophages due to spe-
cific recognition, carrying the previously bound HIV-VLPs.
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2 MATERIALS AND METHODS 
 
 
2.1 Materials 
 
2.1.1 Biological material 
  
 Cell lines  
Name Species Origin Source 
HEK-293T Homo sapiens Kidney, epithelial ATCC® CRL-11268 
HeLa Homo sapiens Cervix, epithelial ATCC® CCL-2 
COS-7 Cercopithecus aethiops Kidney, fibroblast ATCC® CRL-1651 
J774A.1 Mus musculus Monocyte, macro-
phage 
Kindly provided by Prof. Dr. Thomas Meyer  
MDCK Canis familiaris Kidney, epithelial ATCC
® CCL-34 
  
Plasmids and siRNA oligonucleotides  
Name Insert Source 
pEGFP Gag AIDS Reagents 
pEGFP Rab7 Kindly provided by Prof. Dr. Volker Hauke 
pcDNA3.1 p96ZM651gp160-CD5-opt AIDS Reagents 
pYFP Tau Kindly provided by Dr. Maik J. Lehmann 
pCFP Syt-VII Kindly provided by Prof. Dr. T. Südhof 
pBAD-His-B MediumFT/FastFT Kindly provided by Prof. Dr. V. Verkhusha 
Silencer Select 
SYT7 (ID:s17291) 
 Life Technology 
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The Gag-EGFP plasmid was restricted with BamHI and BsrGI in order to substi-
tute EGFP with the following constructs: CFP, mCherry, MediumFT and FastFT. 
 
2.1.2  Lipids and proteins  
 
Molecular structures of the lipids are reported in the Appendix. 
Name Source 
L-Į-phosphatidylcholine (Egg-PC) (Egg, Chicken) Avanti Polar Lipid 
1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-(cap-biotinyl)(Biotin-
cap-PE) 
Avanti Polar Lipid 
1-palmitoyl-2 (dipyrrometheneborondifluoride) undecanoyl-sn- glycero-3- 
phosphocholine (TopFluor PC) 
Avanti Polar Lipid 
1,2-Diacyl-sn-glycero-3- phospho-L-serine Sigma 
Streptavidin Sigma 
 
2.1.3 Media and solutions 
 
 Cell culture media and reagents 
Application Composition Source 
Cell growth 
(HeLa, HEK-293T, MDCK, COS-7) 
DMEM: 10% fetal calf serum, 200mM L-
glutamine,  1% Penicillin/Streptomycin 
GE Healthcare 
Cell growth 
(J774A.1) 
RPMI: 10% fetal calf serum, 200mM L-
glutamine, 1% Penicillin/Streptomycin 
GE Healthcare 
Cell passaging 
 
PBS: with/without 100 mg/ml Ca2+ and 
Mg2+PBS with 0.5 mg/ml Trypsin, 0.22 
mg/ml EDTA 
GE Healthcare 
Cell freezing medium 70 % DMEM 20 % fetal calf serum 10 % 
DMSO 
GE Healthcare 
Transfection Turbofect Fermentas 
Transfection/RNAi Lipofectamine 2000 Life Technologies 
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Buffers 
Buffer Composition 
PBS 137 mM NaCl  
2.7 mM KCl 
10 mM Na2HPO4 + 2 H2O, 1.76 mM KH2PO4 
TNE Buffer 20 mM Tris-HCl 
100 mM NaCl 
1 mM EDTA  
(pH=7.5) 
Stacking SDS-gel buffer 1 M Tris/HCl pH 6.8 
Separating SDS-gel buffer 1 M Tris/HCl pH 9.0 
SDS loading buffer 63 mM Tris/HCl, 10 % glycerol,2 % SDS, 0.0025 % Bromophenol 
blue100 mM -mercaptoethanol 
SDS running buffer 25 mM Tris/HCl, 192 mM glycine, 0.1 % SDS 
 
2.1.4 Reagents 
 
Standard chemicals were obtained from Merck, Sigma and Roth. 
 Chemicals and fluorescent markers 
Name Source 
U73122 TOCRIS Bioscience 
Mepyramine TOCRIS Bioscience 
Tert-butylhydroquinone TOCRIS Bioscience 
Thapsigargin ENZO Lifesciences 
Cytochalasin D TOCRIS Bioscience 
Dynasore Sigma Aldrich 
Dimethylsulfoxid Sigma Aldrich 
Propidium Iodide Sigma Aldrich 
Name Source 
Lysotracker Life Technologies 
Hoechst 33342 Life Technologies 
Mitotracker Life Technologies 
ER-Tracker Life Technologies 
DiI Life Technologies 
Fura2-AM Life Technologies 
Fluo5F-AM Life Technologies 
MATERIALS AND METHODS 
 
 
31 
Antibodies 
Name Source 
anti-p24 (mouse)  Millipore 
anti-gp120 biotin conjugated (goat) Abcam 
IRDye-680 anti-mouse LI-COR Bioscience 
IRDye-800 anti-goat LI-COR Bioscience 
2.1.5 Kits 
 
Name Source 
Pierce BCA Protein Assay Kit Thermo Scientific 
QIAprep Spin MiniPrep Kit Quiagen 
Plasmid MaxiPrep Kit Quiagen 
Celltiter Blue Cell Viability Assay Promega 
 
2.1.6 Consumables 
 
Material Source 
Cell culture flasks (T25, T75) Nunc 
Cell culture plates12-well Nunc 
100 nm polycarbonate filters Avanti polar Lipid 
Cell scraper Sarstedt 
Cryo tubes (1.5 ml) Sarstedt 
Glass bottom petri dishes MatTek 
Filtropur 0.45 ǋm SARSTED 
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2.1.7 Equipment 
 
Name Configuration 
Olympus FV-1000 IX-81 microscope - 60x/1.2 Water UPlanSApo 
405, 560 nm diode lasers 458, 488, 515 nm Argon laser  
3 confocal PMTs; Climatization chamber 
Olympus FV-1000MPE IX-81 microscope- 60x/1.2 Water UPlanSApo 
405, 440, 560, 635 nm diode lasers (458), 488, 515 nm Argon 
laser 
3 confocal PMTs;Climatization chamber 
Olympus IX-81  
(Epifluorescence microscope) 
HBO lamb 100x/1.35 Oil UPlanFL, DIC 
Oil ZeissFilter cube: U-MWU2: BP330-385 BA420 DM400 
(DAPI) 
BD FACSAria II 375, 488, 405, 633 nm laser line Filters: 515 - 545 nm, 564 - 
606 nm, 600 - 620 nm 
 
2.1.8 Software 
 
Name Supplier 
Olympus FV1000 3.1 Olympus 
FACS Diva Software Backton Dickinson 
FlowJo Tree Star, Inc. 
ImageJ US National Institute of Health (NIH) 
MetaMorph Molecular Devices 
Matlab The Mathworks 
Prism GraphPad Software, Inc. 
Keynote Macintosh 
Microsoft Office 2011 Microsoft 
Papers2 Macintosh 
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2.2 Methods 
 
Cell culture 
The cells were propagated in growth medium in 75 cm2 culture flasks at 37 °C 
and 5% CO2. The cells were passaged every 3 - 5 days before they had reached full 
confluence. To this end, the cells were washed twice with PBS and detached using 
trypsin-EDTA at 37 °C for 5 - 15 min. Trypsinization was stopped by addition of 
growth medium and approximately 1x106 cells were seeded in a new 75 cm2 culture 
flask. In the case of J774A.1 macrophages, the cells were scraped off in the pres-
ence of 2 ml PBS. For the different assays, cells were seeded into 6-, 12-well plates 
or petri dishes. For long term storage, the cells from one 75 cm2 culture flask were 
detached, pelleted for 5 min at 2000 g and re-suspended in freezing medium. The 
cells were kept at -80 °C for 24 hours and subsequently stored in liquid nitrogen. 
 
Transfection 
Cells were transfected with expression-plasmids using Turbofect according to 
the manufacturers manual. To this end, cells were seeded in 35 mm glass bottom 
petri dished and grown until they reached 70 - 90 % confluence. 6 ǋl Turbofect and 
4 ǋg DNA were diluted in 400 ǋl serum-free medium and incubated for 20 min at 
room temperature. The cells were washed in PBS and the DNA/Turbofect mix was 
added with additional 1.5 ml serum-free medium. After 4 h the medium was 
changed to growth medium.  
 
RNA interference 
For siRNA experiments, cells were always co-transfected with Gag-EGFP and 
0.02 ǋM SYT7-siRNA oligonucleotides (5 pmol in 250 ǋl transfection volume) ac-
cording to the manufacturers manual. To this end, cells were seeded and grown 
until they reached 70 - 90 % confluence. 5 ǋl Lipofectamine 2000 were diluted in 
250 ǋl serum-free medium, and 4 ǋg Gag-EGFP together with 0.02 ǋM siRNA oligo-
nucleotides were diluted separately in 250 ǋl serum-free medium. After 5 min, the 
two solutions were mixed together and incubated for 20 min at room temperature. 
The cells were subsequently washed in PBS and the co-transfection/Lipofectamine 
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mix was added with additional 1.5 ml serum-free medium. After 4 h the medium 
was changed to growth medium. 
 
Confocal microscopy live imaging on HeLa and COS-7 
The cells were plated in a 2 mm glass-bottom dish two day before analysis. 
One day after plating, the cells were transfected with the indicated plasmid(s) with 
the transfection reagent Turbofect, as described before. 24 hours after transfection, 
the cells were washed with PBS and either stained with intracellular markers (see 
detailed experiments in the Results section) or directly observed under the confocal 
microscope. Live-cell imaging of intracellular localization of Gag or co-localization 
with intracellular compartments or structures was performed always at 37°C, 5% 
CO2 with an Olympus FV-1000MPE laser-scanning confocal microscope (Olympus, 
Shinjuku, Tokyo, Japan). Fluorescence emissions of Lysotracker/mCherry/ER-
tracker/Mitotracker, EGFP/Fluo5F, CFP, Hoechst 33342, and YFP were measured at 
590 nm, 509 nm, 475 nm, 454 nm and 530 nm, respectively. If indicated, before 
microscopy, the cells were treated with specific reagents diluted in DMSO (e.g. 
U73122, Mepyramine, TBHQ) for the indicated time at 37°C, 5% CO2. The final 
concentration of DMSO in the cell medium was always equal or below 0,1% of the 
total volume. 
 
Total Internal Reflection Fluorescence Microscopy  
TIRFM was used to study the plasma membrane localization of the expressed 
protein. An inverted FluoView 1000MPE microscope was modified with a beam ex-
pander to allow illumination of the whole field of view using laser excitation sources 
and a highly sensitive, cooled Hamamatsu Orca ER CCD- camera for epifluores-
cence observation. The tilting of the angle of the incidenting light beam was 
achieved by a displacement of the beam, away from the center of the observation 
objective179 (60x UplanSApo oil objective with a numerical aperture 1.45 ). In a 
typical TIRFM experiment, the glass-attached parts of the cells under study were 
focused and imaged in the epifluorescence mode applying beam expander and 
CCD-camera. Then, the TIRFM angle was tilted until the out-of-focus light from in-
tracellular structures disappeared and plasma membrane structures dominated the 
image. As a rule of thumb, if the angle is right, changes of the focus should not 
change the structures displayed but only the sharpness of the plasma membrane 
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components. Since only an evanescent field of the excitation light was used to illu-
minate the fluorophores, high laser intensities of around 50% and image acquisition 
times of at about 1 second were used. 
 
Intracellular calcium staining with Fluo5F-AM 
The cells were plated in a 2 mm glass-bottom dish one or two (in the case of a 
transfection) day before analysis. The cells were stained with 3 ǋM Fluo5F-AM for 
35 minutes at at 37°C, 5% CO2. The cells were then washed with PBS and complete 
culture medium (DMEM) was added. Fluo5F-AM was aliquoted in DMSO. The final 
concentration of DMSO in the cell medium was always equal or below 0,1% of the 
total volume. 
 
Confocal live-imaging of Fluorescent Timers  
The cells were plated in a 2 mm glass-bottom dish two days before microscopy. 
24 hours before microscopy the cells were transfected with either Gag-FastFT or 
Gag-MediumFT. Live-cell imaging of the transfected cells was performed at the 
Olympus FV-1000MPE microscope. The During the FT maturation, the fluorescence 
of the blue forms increased to its maximum value, and after that decreased to zero 
(Table 1).  
 
Fluorophore Ex Peak (nm) Em Peak (nm) Characteristic time at 37°C (hours) 
FastFT 
Blue form 403 466 0.25 
Red form 583 606 7.1 
MediumFT 
Blue form 401 464 1.2 
Red form 579 600 3.9 
Table 1. Properties of the blue and red forms of the FTs at 37°C. The indicated characteristic 
times correspond to fluorescence maxima for the blue forms, and to maturation half times for the red 
forms. 
 
The fluorescence of the red forms increased with time with some delay and then 
reached a plateau. At 37°C the maxima of the blue fluorescence intensities are ob-
served at 0.25 and 1.2 for the fastFT and the mediumFT, respectively. The half-
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maxima of the red fluorescence intensities were reached at 7.1 and 3.9, respective-
ly, which corresponds to the half-times of the maturation for the red FT forms. Fluo-
rescence emissions of the blue and the red form were measured at 454 nm and 590 
nm, respectively. 
 
Confocal microscopy live imaging on macrophages 
Macrophages were plated in a 2 mm glass-bottom dish one day before analysis. 
Acidic compartments were marked using Lysotracker as described in the product’s 
guidelines. The cells were then washed and treated with ĮEnv-PS-LUVs and HIV-
VLPs as described above. Live-cell imaging of intracellular co-localization of ĮEnv-
PS-LUVs and HIV-VLPs in acidic compartments was performed in an environmental 
chamber at 37°C, 5% CO2 with an Olympus FV-1000MPE laser-scanning confocal 
microscope (Olympus, Shinjuku, Tokio, Japan). Fluorescence emissions of 
Lysotracker, EGFP and DiI were measured at 590 nm, 509 nm and 564 nm, respec-
tively. Percentage of HIV-VLPs/ acidic compartments co-localization was obtained 
calculating the areas (i.e. number of pixels) of dots corresponding to the fluores-
cent signal of EGFP (HIV-VLPs) overlapping with pixels corresponding to the signal 
of Lysotracker (acidic compartments). The co-localization was calculated as a ratio 
of overlapping area and total pixel area occupied by HIV- VLPs, expressed as a per-
centage, and averaged over ten different confocal micrographs using CellProfiler 
(Broad Institute, Cambridge, MA). In order to identify the HIV-VLPs and distinguish 
them from the autofluorescence signal, a user-defined threshold was selected. 
 
Calcium-release in macrophages 
Macrophages were seeded into MatTek dishes a day before analysis. Subse-
quently, cells were stained with 3 einther incubated with 3 ǋM Fura2-AM for 35 
minutes at at 37°C, 5% CO2. The cells were then washed with PBS and complete 
culture medium (RPMI) was added. Fluo5F-AM was aliquoted in DMSO. The final 
concentration of DMSO in the cell medium was always equal or below 0,1% of the 
total volume. After calcium staining, the cells were observed at the Olympus IX-81 
epifluorescence microscope. The release of intracellular calcium was measured live, 
upon addition of either ĮEnv-PS-LUVs or ĮEnv-LUVs. The emission was detected at 
420 nm. For preliminar ER-calcium depletion, the cells were treated with 10 ǋM 
Thapsigargin for 1 hour at 37°C, 5% CO2 before adding the immunoliposomes. 
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Correlative Light and Electron Microscopy 
HeLa, COS-7 or J774A.1 macrophages were seeded into a 35-mm gridded 
MatTek dish. Subsequently, cells were either transfected with the indicated con-
struct or, one day after seeding, incubated for 1 hour with HIV-VLPs and ĮEnv-PS-
LUVs as described in the Results section and fixed for 20 minutes at room tempera-
ture with 2.5% (v/v) glutaraldehyde and 2% (w/v) paraformaldehyde in PBS. For 
fluorescence microscopy, the cells were imaged with an Olympus FV- 1000MPE la-
ser-scanning confocal microscope. For subsequent electron microscopy, cells were 
rinsed three times for 5 minutes with 100 mM cacodylate buffer (pH=7,4), post-
fixed for 1 hour in 1% (v/v) osmium tetroxide, rinsed three times with distilled wa-
ter, en bloc stained with 0.5% (w/v) uranyl acetate, dehydrated through a graded 
ethanol series and finally embedded using EMBed 812 (EMS). Cells within a region 
previously identified by confocal microscopy were cut en face and 70-90 nm sec-
tions were collected. Sections were counterstained with 4% (w/v) uranyl acetate 
followed by lead citrate. All samples were imaged on a Zeiss EM 900 transmission 
electron microscope equipped with a wide-angle CCD camera (TRS-System, 
Moorenweis, Germany). Correlation of fluorescence images and electron micro-
graphs was accomplished through alignment of cell surface structures. 
 
Preparation of liposomes 
The lipids were dissolved in chloroform to 5-10 mM stock concentration. To 
prepare 100 nm diameter LUVs, lipids were mixed and dried under nitrogen fol-
lowed by high vacuum for at least 30 minutes. The amounts of lipids in the mix-
tures were: 1) sample “LUVs”, 99.95mol% Egg-PC, 0.05 mol% TopFluorPC: 2) 
sample “PS-LUVs”, 30mol% PS, 69.95mol% Egg-PC, 0.05mol% TopFluorPC; 3) 
samples “ĮEnv-PS-LUVs and ĮEnv-LUVs”: 30% (or 0 mol% for ĮEnv-LUVs) PS, 
68.95% (or 98.95% for ĮEnv-LUVs) Egg-PC, 1 mol% Biotin-cap-PE, 0.05 mol% DiI; 
4) “ĮEnv-PS-LUVs and ĮEnv-LUVs” samples used in the toxicity tests: 30 mol% (or 
0 mol% for ĮEnv-LUVs) PS, 69 mol% (or 99 mol% for ĮEnv-LUVs) Egg-PC, 1 mol% 
Biotin-cap-PE. The lipid mixtures described above were then re-suspended in PBS 
without Ca2+ and Mg2+, vortexed and passed through 100 nm polycarbonate filters 
11 times using a Mini-Extruder (Avanti Polar Lipids) in order to obtain LUVs of uni-
form size. All LUV samples were extruded directly at 300 ǋM and subsequently di-
luted to the desired concentration. To obtain antibody-decorated liposomes (ĮEnv-
PS-LUVs and ĮEnv-LUVs), 2.5 ǋL (1 mg/mL) of streptavidin and 4 ǋL (50 ǋg/mL) of 
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ĮEnv-Abs (polyclonal anti-HIV-1 gp120-biotin conjugated) were pre-mixed for 30 
minutes at 4°C, then added liposomes with or without PS (total volume 100 ǋl, lipid 
concentration 300 ǋM) and further incubated for 1 hour at room temperature. In 
the text, both ĮEnv-PS-LUVs and ĮEnv-LUVs are sometimes referred to as “immu-
noliposomes”. 
 
HIV-VLPs uptake by macrophages 
The mouse macrophage cell line J774A.1 was used to study the uptake of HIV-
VLPs in the presence of immunoliposomes. Cells were grown to 70% confluency in 
12 mL cell-flasks in the presence of RPMI, 10% FBS, 1% penicillin-streptomycin, 
and 2 mM L-glutamine. Then, cells were gently scraped off, plated in a 12-well plate 
and incubated at 37°C in 5% CO2 for 24 hours. 100 ǋL (300 ǋM) of ĮEnv-PS- LUVs 
(or ĮEnv-LUVs) and 20 ǋL (from a 0.81 mg/mL stock solution) HIV-VLPs were 
mixed together for 1 hour at room temperature. The cells were washed with PBS 
and treated with the liposomes/HIV-VLPs mix for 1 hour in RPMI medium (up to 1 
mL total volume) at 37°C with 5% CO2. Then, the medium was removed, the cells 
were washed with PBS and gently scraped off in the presence of PBS for flow cy-
tometry measurements. 
 
Production and purification of HIV-VLPs 
HEK-293T cells were grown in the presence of DMEM, 10% FBS, 1% penicillin-
streptomycin, and 2 mM L-glutamine and plated in a 100x 20 mm tissue-culture 
dish. Once the cells reached 90% confluence (usually after 24 hours), they were 
co-transfected either with pGag-EGFP alone or together with p96ZM651gp160-CD5-
opt using the transfection reagent Turbofect. Transfection medium was replaced 3-4 
hours after transfection and collected 48 hours later for HIV-VLPs purification. HIV-
VLPs were purified as previously described [18]. Briefly, medium from transfected 
cells was filtered through a 0.45 ǋm pore-size filter (Filtropur S 0.45). The filtrate 
was layered on top of a 20% sucrose cushion and centrifuged at 4°C for 2 hours at 
28000 rpm in a SW40Ti rotor. Finally, the HIV-VLPs pellet was re- suspended in 200 
ǋl TNE buffer. Purified HIV- VLPs were analyzed by western blot. 
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Western blot and protein quantification in HIV-VLPs 
The presence of Gag-EGFP and/or Env in the HIV-VLPs was determined by 
western blot with mouse anti-p24 and goat anti-gp120-biotin conjugated antibod-
ies. HIV-VLPs were separated by electrophoresis through 10% SDS-polyacrylamide 
gels and electroblotted onto nitrocellulose membrane. Following incubation with 
appropriate primary and secondary antibodies, proteins were visualized using an 
infrared-based imaging system (Odyssey; LiCor Biosciences, Lincoln, NE, USA). To 
quantify the protein content of the purified HIV-VLPs containing solution, different 
amounts of HIV-VLPs were subjected to reducing SDS-PAGE (10%, pH=7.5). The 
same was done for concentration series of a BSA reference. The obtained coomass-
ie-stained polyacrylamide gel (not shown) was imaged using a LI-COR Odyssey 
Scanner and the band intensities were analyzed with the ImageJ Software. By com-
parison between the resulting band intensities from the HIV-VLPs samples with the 
concentration series of BSA standard, it was possible to estimate the protein con-
tent of purified HIV-VLPs stock solution. 
 
Flow cytometry measurements and fluorescence intensity quantifica-
tions 
Macrophages were analyzed in PBS using a BD FACS Aria II Flow Cytometer 
(BD Biosciences, San Jose, CA, USA) with a 100 ǋm nozzle and 2.0 ND filter. A total 
of 10,000 events were counted and the fluorescence values of HIV-VLPs and ĮEnv-
PS-LUVs or PS-LUVs/LUVs alone were measured. The presence of internalized 
EGFP-tagged HIV-VLPs was quantified by exciting at 488 nm and detecting with a 
530/30 band-pass filter. The presence of internalized DiI-labeled liposomes was 
quantified by exciting at 561 nm and detecting with a 616/23 band-pass filter. The 
presence of internalized Top- Fluor-PC-labeled liposomes was quantified using the 
same settings for HIV-VLPs. Quantification of fluorescence intensities was per-
formed using the software FlowJo. 
 
Toxicity test 
Toxicity of the treatment with HIV-VLPs in the presence of immunoliposomes on 
the mouse macrophage cell line J774A.1 was tested. Cells were grown to 70% con-
fluency in 12 mL cell-flasks in the presence of RPMI, 10% FBS, 1% penicillin-
streptomycin, and 2 mM L-glutamine. Then, cells were gently scraped off, plated in 
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a 96-well plate and incubated at 37°C in 5% CO2 for 24 hours. ĮEnv-PS- LUVs HIV-
VLPs were mixed together for 1 hour at room temperature. The cells were washed 
with PBS and treated with the liposomes/HIV-VLPs or 10% DMSO, and incubated 
for 1, 48 or 72 hours at at 37°C with 5% CO2in RPMI medium (up to 200 ǋl total 
volume per well). Subsequently, the cells were washed and the CellTiter-Blue test 
was performed according to the manufacturers manual. The fluorescence emission 
of the fluorescent dye was measured at a plate-reader. For the test with propidium 
iodide, the cells were re-suspended in PBS, stained with 1 ǋl PI (from a 10 ǋg/mL in 
PBS stock solution) and the fluorescence of PI was measured with FACS by exciting 
at 561 nm and detecting with a 616/23 band-pass filter. 
 
Statistical analysis 
In order to compare different datasets and verify whether they were signifi-
cantly different, we performed Student's t-tests.  
The associated probabilities were calculated using the Matlab function ttest2 
(Matlab, The Mathworks Inc., Natick MA). Two datasets were considered significant-
ly different if the calculated probability p was lower than 0. 
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3 RESULTS AND DISCUSSION 
 
 
3.1 Intracellular distribution and dynamics of HIV-1 Gag, 
and calcium-dependent release of virus-like particles  
 
The first aim of this work was to study the intracellular distribution and dynam-
ics of HIV-1 Gag and to unravel calcium-dependent mechanisms able to mediate 
the release of VLPs from the host cell. To these aims, experiments were conducted 
with a combination of confocal and total internal reflection fluorescence microscopy, 
and correlative-light and electron microscopy.  
The study of VLPs release in permissive (COS-7, HEK-293T) and non-permissive 
(HeLa) cell lines, and chemical modulation of intracellular pathways, allowed the 
identification of an alternative mechanism for VLPs release.  
 
3.1.1 Intracellular distribution of HIV-1 Gag 
 
Expression in appropriate mammalian cell lines (e.g. HeLa, COS-7, HEK-293T) 
of a fluorophore-tagged version of Gag (e.g. Gag-EGFP5, Gag-CFP6, Gag-mCherry) 
allows studying, e.g. by confocal fluorescence microscopy, the intracellular localiza-
tion of the Gag protein in a way that highly resembles the distribution of the wild-
type Gag in the context of a HIV-1 infection [2,103]. In Figure 13 a HeLa cell 24 
hours after transfection with a Gag-EGFP plasmid is shown. As it can seen in the 
merged panel with the DIC_ images and by the shape and the size of the nuclear 
staining, Figure 13A and 13B show the same cell in two different confocal planes: in 
the middle of the cell and at the bottom, respectively. In these images, Gag-EGFP 
can be found intracellularly in two different distribution patterns: I) associated to 
the PM and II) in a dot-like form in the perinuclear and cytosol area. Depending on 
the expression level and the timing after protein expression, Gag can also be ob-
                                          
5 (EGFP) Enhanced green fluorescent protein 
6 (CFP) Cyan fluorescent protein 
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served in a third distribution pattern, as shown in Figure 16 and 19: III) homoge-
neously distributed in the cytosol. Total internal reflection fluorescence microscopy 
(TIRFM) imaging is a technique for the identification of fluorescent molecules spe-
cifically localized at the basal PM - very near to the support (see Material and Meth-
od section for further details). Visualization of a Gag-EGFP transfected cell in 
TIRFM-modus (Figure 13C) allows therefore the visualization of the Gag distribution 
at the basal PM. 
 
 
Figure 13. Live cell confocal microscopy of Gag-EGFP transfected HeLa cells. The focal plane was 
positioned approximately at the middle of cell height (A) or at the bottom of the sample (B). Gag-EGFP 
(green channel) is localized in two distribution patterns: I) associated to the PM and II) in a dots-like 
form in the perinuclear and cytosol area. DNA staining (blue channel) indicates the location of the nucle-
us and helps to identify the position of the confocal plane. (C) TIRFM modus of the image shown in (B). 
Gag-EGFP is shown here in the white channel. Scale bar is 5 μm. Images were collected 24 hours after 
transfection at 37°C, 5% CO2. 
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3.1.2 Activation of both Gq-protein and receptor-protein tyrosine 
kinase - dependent phospholipase C is required for Gag 
transport to the PM 
 
Many host factors are believed to play an important role supporting different 
steps of HIV-1 assembly and release. A previous study has shown that activation of 
phospholipase C (PLC) in COS cells is required for efficient release of VLPs from 
host cell [1,43]. The reason why the PLC might play an important role regulating 
the release of VLPs remains to be understood. Nevertheless, inhibition of PLC in 
COS cells was shown to keep Gag in an aggregate conformation in the perinuclear 
area [1]. In this work, the use of TIRFM on HeLa cells transfected with Gag-EGFP 
enabled to confirm the previously obtained results and to further characterize the 
effects on PLC inhibition on Gag trafficking to the PM. Analysis of VLPs-release in 
HEK-293T upon modulation of the PLC pathway added new information on the role 
of the PLC signaling pathway. 
Figure 14 shows how upon inhibition of PLC (with 10 μM of the PLC inhibitor 
U73122), besides a decrease in Gag protein expression, a strong reduction of the 
presence of Gag at the PM, compared to untreated cells (Figure 13) and aggrega-
tion in the perinuclear area can be observed. The inhibitor U73122 is able to block 
the activation of both Ǆ and ǃ isoforms of the PLC in many different cell types 
[104,105]. The enzymatic activity of these two isoforms of PLC is triggered by two 
different pathways: the Ǆ isoform is activated by the tyrosine-kinase receptor (TKR) 
and the ǃ isoform by the G-protein coupled receptor (GPCR) [106]. Specific inhibi-
tion of the "q" isoform (Gq) of the G-protein with 10 μM of the Gq-protein inhibitor 
mepyramine [107], caused aggregation of Gag in the perinuclear area (Figure 15A) 
and resulted in a reduced release of VLPs (from HEK-293T cells) (Figure 15B). 
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Figure 14. Inhibition of PLC activity blocks Gag in aggregates and strongly decreases Gag 
localization at the PM. The focal plane was positioned approximately at the middle of cell height (A) or 
at the bottom of the sample (B). Gag-EGFP (green channel) is localized in aggregates in the perinuclear 
area. DNA staining (blue channel) indicates the location of the nucleus and helps to identify the position 
of the confocal plane. (C) TIRFM modus of the image shown in (B). Gag-EGFP is shown here in the white 
channel. Scale bar is 5 μm. Images were collected 24 hours after transfection at 37°C, 5% CO2 
 
 
 
Figure 15. Inhibition of Gq-protein activity blocks Gag in aggregates in the cytosol and reduc-
es VLPs release. (A) The focal plane was positioned approximately at the middle of cell height. Gag-
EGFP (green channel) is localized in aggregates in the perinuclear area. DNA staining (blue channel) 
indicates the location of the nucleus and helps to identify the position of the confocal plane. Scale bar is 
6 μm. Images were collected 24 hours after transfection at 37°C, 5% CO2. (B) Western blot of purified 
VLPs from untreated (control) and Mepyramine-treated (+Mepyramine) HEK-293T cells, visualized after 
staining with an anti-p24 antibody. 
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3.1.3 Gag, assembled in VLPs, is entrapped into vesicles of the 
endo-lysosomal system 
 
While the Gag population at the PM (previously mentioned as distribution-
pattern I) most probably corresponds to monomeric/polymeric PM-bound Gag or 
nascent VLPs, and the cytosolic spread state (distribution-pattern III) represents 
freely distributed Gag proteins into the cytosol [2], the nature of the observed in-
tracellular dots might need further characterization. The distribution pattern of Gag 
in a dot-like form, in the cytosol and the perinuclear area (previously mentioned 
distribution-pattern II), mostly resembles the distribution of vesicles of the endo-
lysosomal system [108]. Endosomal and lysosomal vesicles can be distinguished by 
different parameters (e.g. associated GTPases, specific membrane receptors, proton 
content) [102,108]. However, one characteristic is common to all of these vesicles: 
a high intralumenal calcium concentration [109]. Staining with the low-affinity cal-
cium fluorophore Fluo5F, which is known to localize in intracellular high-calcium 
containing compartments (e.g. ER in renal cells [110]), was applied. Interestingly, 
in HeLa cells Fluo5F detects the presence of calcium in an intracellular dot-like dis-
tribution pattern, which mostly co-localizes with the Gag-CFP dots (Figure 16).  
 
 
Figure 16. Gag-CFP intracellular dots co-localize with Fluo5F. The focal plane was positioned ap-
proximately at the middle of cell height. Intracellular dots of Gag-CFP (magenta channel) co-localize with 
Fluo5F dots (green channel) in the perinuclear area. Scale bar is 5 μm. Images were collected 24 hours 
after transfection at 37°C, 5% CO2. 
 
Furthermore, live-cell imaging of Gag-CFP transfected cells stained with Fluo5F 
showed that the Gag/Fluo5F co-stained vesicles move in the intracellular space fol-
lowing straight trajectories, moving from and to the PM (data not shown).  
In order to further characterize the intracellular co-localization of Gag-CFP and 
Fluo5F with high spatial resolution, a correlative fluorescence and electron micros-
copy imaging approach was used. Figure 17 shows that Gag-CFP/Fluo5F-positive 
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compartments are membrane-delimited vesicles containing Gag assembled in VLPs. 
Vesicles of the endo-lysosomal system are not the only calcium-containing com-
partments in mammalian cells. Co-localization with other calcium-containing com-
partments (e.g. mitochondria, ER, nucleus) must be investigated. To this aim, co-
staining with Fluo5F, a DNA-, a mitochondrial-, and an ER-marker was performed 
(Figure 17 and Figure 18). As shown by the images, Fluo5F stained vesicles do not 
co-localized either with the nucleus, the mitochondria or the ER. Subsequently, 
Gag-CFP transfected HeLa cells, stained with Fluo5F, were either co-stained with the 
lysosomal marker Lysotracker or co-transfected with a fluorophore-tagged version 
of the Rab7 protein (i.e. Rab7-GFP) as marker for LE. As shown in Figure 19, indi-
cated by the arrows, Fluo5F stains at least two different kind of vesicles of the en-
do-lysosomal system: LEs and LYs. Gag is contained in both compartments (Figure 
19A and B).  
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Figure 17. Co-localized Gag/Fluo5F dots correspond to VLPs-containing intracellular com-
partments. (B-C) Gag-CFP (red channel) and Fluo5F (green channel) were visualized by confocal laser 
scanning microscopy 24 hours after transfection, and correspond to endosome-like structures containing 
VLPs imaged by transmission electron microscopy (E-G). (A, E-G) electron micrographs, (B-C) correla-
tion of fluorescence images with electron micrograph by alignment of cellular surface structures. Indicat-
ed squares represent the area of magnification in the subsequent panel. Scale bars: 5 μm (A-B), 2 μm 
(C), 1 μm (E), 500 nm (F). 
 
 
Figure 18. Fluo5F does not co-localize with mitochondria or ER. The focal plane was positioned 
approximately at the middle of cell height. Intracellular dots of Fluo5F (green channel) do not co-localize 
with (A) mitochondria (red channel) or (B) ER (red channel). DNA staining (blue channel) indicates the 
location of the nucleus. Scale bar is 4 μm. Images were collected at 37°C, 5% CO2. 
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Figure 19. Intracellular Gag dots partially co-localize with Fluo5F and LY/LE. The focal plane 
was positioned approximately at the middle of cell height. Intracellular dots of Gag-CFP (magenta chan-
nel) co-localize with Fluo5F dots (green channel) in the perinuclear area. In the merged image in (A), 
shown by the arrows, Gag-CFP and Fluo5F co-localize with Lysosomes (red channel). In the merged 
image in (B), shown by the arrows, Gag-CFP and Fluo5F co-localize with Rab7-GFP (red channel) Scale 
bar is 2 μm. Images were collected 24 hours after transfection at 37°C, 5% CO2. (C) Schematic repre-
sentation of the maturation pathway of LEs to LYs and the possible fates of the two different compart-
ments. 
 
Clearly, Gag assembled in VLPs exists intracellularly in calcium-containing, mem-
brane-delimited intracellular vesicles that belong to the endo-lysosomal system. 
These compartments can be specifically identified as LEs and LYs. The fate of the 
entrapped VLPs is unclear and needs further investigations. Figure 19C shows a 
schematic representation of the maturation pathway of LEs to LYs and the possible 
fates of the two different compartments.  
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3.1.4 Lysosomal calcium leakage induces release of VLPs from 
HeLa cells 
 
Previous studies have shown that induction of a transient rise in cytoplasmic 
calcium increased the amounts of VLPs in LEs/MVBs/LYs, and resulted in a dramatic 
enhancement of VLPs release [2,44]. However, although cellular factors have been 
already proposed as mediators of calcium provision (e.g. ER [1]), how calcium can 
promote the release of VLPs remains to be determined. In order to further investi-
gate the role of intracellular calcium in VLPs release, it is intriguing to investigate 
whether the calcium of lysosomal origin might also play a role affecting the release 
of VLPs. In fact, calcium release from LYs is known to be specifically activated in the 
case of membrane injuries [111]. More in detail, the calcium released from LYs can 
then trigger fusion between lysosomal and late-endosomal vesicles, causing the 
formation of hybrid LY/LE organelles inducing therefore a intralumenal content mix-
ing [112,113] (for a schematic representation, see Figure 35). Furthermore, gener-
ally, elevation of cytosolic calcium triggers fusion of LYs with the PM and release of 
lysosomal content into the extracellular space [102]. More specifically, wounding 
the PM by scratching induces the surface exposure of the major lysosomal mem-
brane glycoprotein Lamp-1 at the wound site as a consequence of intracellular cal-
cium release [114]. This mechanism has been described as LY-mediated PM-repair 
[112]. VLPs contained in LYs and/or LEs might be not completely destined to degra-
dation, but rather indirectly “recycled” from such PM-repair mechanism, which in-
volves release of calcium from LYs and subsequently multiple fusion processes. 
Gag-CFP transfected HeLa cells, stained with Fluo5F, were treated for 3 hours with 
the SERCA73-ATPase inhibitor t-Butylhydroquinone (TBHQ), and then observed at 
the confocal microscope. TBHQ inhibits the re-captation of calcium into LYs, block-
ing the activity of the SERCA3-ATPase [115], and inducing therefore a leakage of 
calcium from lysosomal compartments that express the SERCA3-ATPase on their 
surface (see schematic representation in Figure 20B). Surprisingly, induced calci-
um-leakage from LY, instead of causing a loss of Fluo5F fluorescence from those 
compartments, resulted in a dramatic enlargement of Fluo5F-positive vesicles (i.e. 
endo-lysosomes), and their spread distribution among the cytosol (Figure 20A). 
Furthermore, treatment with TBHQ for 3 hours, 48 hours after transfection with 
                                          
7 (SERCA) Sarcoplasmic/endoplasmic reticulum calcium ATPase 
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Gag-CFP, resulted in release of a small amount of VLPs (Figure 20C). HeLa cells are 
known to be unable to allow the release of VLPs, because of the constitutively ex-
pression of Tetherin, whose inhibitory activity on VLPs release can be counteracted 
only by the presence of the HIV-1 protein Vpu [116,117]. Collection of VLPs from 
Gag-transfected HeLa cells, after treatment with TBHQ, suggests that there might 
be some other mechanism, correlated with the leakage of calcium from LYs, which 
might enable the release of VLPs from HeLa cells.  
 
 
Figure 20. Lysosomal calcium leakage induces enlargement of endo-lysosomal compartments 
and causes release of VLPs from HeLa cells. (A) Gag-CFP transfected cells, stained with 3 μM Fluo5F 
and treated for 3 hours with 1 μM TBHQ. The focal plane was positioned approximately at the middle of 
cell height. Intracellular dots of Gag-CFP (magenta channel) partially co-localize with enlarged Fluo5F 
dots (green channel). Scale bar is 5 μm. Images were collected 24 hours after transfection at 37°C, 5% 
CO2. (B) Schematic representation of the inhibitory activity of TBHQ on LE/LY. Calcium ions and calcium 
fluxes are colored in green; the SERCA3-ATPase is shown in purple, the V-ATPase in orange, and the 
calcium/proton channel in light blue. Protons and protons fluxes are also indicated. The inhibition activity 
of TBHQ is indicated with an interrupted arrow. (C) Western blot of purified VLPs from untreated (con-
trol) and TBHQ treated (+TBHQ) HeLa cells, visualized after staining with an anti-p24 antibody. 
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In order to confirm the results obtained in HeLa cells, specifically regarding the rel-
evance of lysosomal-calcium leakage in the release of VLPs, it is necessary to ex-
press Gag in a different cell-type, which is permissive for VLPs release in absence of 
Vpu protein expression (e.g. COS-7, HEK-293T). In the following paragraphs, the 
intracellular distribution and dynamics of Gag and the release of VLPs will be inves-
tigated in COS-7 cells. COS-7 are also larger than HeLa cells and posses a wide 
microtubule net. These conditions make them appropriate for the study of Gag in-
tracellular dynamics and for the further investigation of the reasons behind the re-
lease of VLPs upon TBHQ treatment. 
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3.1.5 Characterization of Gag intracellular distribution, dynamics 
and VLPs release in COS-7 cells 
 
Transfection of an appropriate cell line, which in contrast to HeLa cells does not 
express Tetherin (e.g. COS-7, HEK-293T cells), with only a Gag-EGFP plasmid, is 
sufficient for the production and the release of VLPs.  
 
 
Figure 21. Intracellular distribution of Gag-EGFP in COS-7 cells and release of VLPs. (A) COS-7 
transfected with Gag-EGFP (green channel). Image was collected 24 hours after transfection at 37°C, 
5% CO2. (B-C) Released VLPs and budding events in COS-7 cells 48 hours after transfection with Gag-
EGFP imaged by transmission electron microscopy. Indicated squares represent the area of magnifica-
tion. White arrows indicate the points of discontinuity in the Gag shell. Scale bars: 6 μm (A), 500 nm 
(B), 300 nm (C). 
 
Budding of VLPs from the PM of Gag-EGFP transfected COS-7 or HEK-293T cells 
results in the release of particles with a discontinuous Gag shell (Figure 21B and 
21C - zoomed sections), in contrast to the evenly distributed ring of Gag density 
A
B C
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that is normally observed beneath the membranes of immature HIV-1 virions and 
Gag VLPs [118]. However, the intracellular distribution of Gag-EGFP in COS-7 cells 
(Figure 21A) can be compared to the previously suggested distribution patterns, 
observed in HeLa cells (see Figure 13 and Figure 16). In order to identify whether 
the different populations of Gag form at specific time points after protein synthesis, 
the EGFP gene in C-terminal of Gag was substituted with two different genes of 
mCherry-derived monomeric variants, called fluorescent timers (FTs), that change 
their fluorescence from blue to red over time [119] (see Material and Method sec-
tion for the cloning procedures).  
 
 
Figure 22. Intracellular distribution of Gag-FastFT and Gag-MediumFT. (A) COS7-cells transfect-
ed with Gag-FastFT. Early fluorescent form of the FastFT (blue channel) and late fluorescent form of the 
FastFT (red channel) are shown. (B) COS7-cells transfected with Gag-MediumFT. Early fluorescent form 
of the MediumFT (blue channel) and late fluorescent form of the MediumFT (red channel) are shown. 
Overlays of the two channels are shown in magenta. Scale bar is 4 μm. Images were collected 24 hours 
after transfection at 37°C, 5% CO2. 
 
FTs can be used as molecular genetically encoded tools to study trafficking of dif-
ferent cellular proteins and to provide accurate insight into the timing of intracellu-
lar processes [119]. The two FTs used in this work are called FastFT and MediumFT, 
in regard to the timing of blue-to-red switch after protein synthesis. The fluores-
Gag- FastFT
Gag- Medium FT Gag- Medium FT
Gag- FastFT Merge
Merge
A
B
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cence switching times of the two FTs are indicated in Table 1 in the Material and 
Method section. Briefly, during the FT maturation the fluorescence of the blue forms 
increase to its maximum value, and after that decrease to zero. The fluorescence of 
the red forms increase with time with some delay and then reach a plateau. At 
37°C the maxima of the blue fluorescence intensities were observed at 0.25 and 
1.2 hours for the FastFT and the MediumFT, respectively. The half-maxima of the 
red fluorescence intensities were reached at 7.1 and 3.9 hours, respectively [119]. 
COS-7 cells transfected with Gag-FastFT (Figure 22A) showed a blue Gag popula-
tion mostly aggregated in dot-like form in the perinuclear area, while the red vari-
ant was found to be poorly concentrated in dots in the perinuclear region but rather 
both spread in the cytosol and near to- or associated to the PM. COS-7 cells trans-
fected with Gag-MediumFT (Figure 22B) mostly resembled the Gag-FastFT trans-
fected cells with the exception of the higher amount of red population of perinuclear 
dots. The convergence of dots in the perinuclear area, particularly notable in a later 
phase after Gag translation (see distribution of the blue and the red forms of Gag-
MediumFT in Figure 22B), together with the previous results obtained in HeLa cells 
(i.e. co-localization in endo-lysosomal compartments), suggest that Gag may move 
exploiting microtubular structures. LEs and LYs are transported on microtubules in a 
bidirectional manner, by the help of both kinesin and dynein motor proteins [120]. 
These motor proteins use ATP to move either from the point of convergence of the 
microtubules (microtubules organization center - abbreviated: MTOC) to the PM 
(kinesins), or vice versa, toward the perinuclear area (dyneins). Maturation of LEs 
to LYs corresponds to a vesicle movement toward the MTOC, where most of the LYs 
localize [108]. On the contrary, vesicles (e.g. LEs and/or LYs) that move from the 
MTOC to the PM are most probably destined to exocytosis or secretion from the PM. 
Live cell confocal microscopy of COS-7 co-transfected with Gag-mCherry and Tau-
YFP (a YFP-tagged version of the microtubule-stabilizing protein Tau) was per-
formed.  
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Figure 23. Distribution of Gag on the microtubular filaments. COS-7 cell co-transfected with Gag-
mCherry (red channel) and Tau-YFP (green channel). The arrows indicate the MTOC and Gag dots appar-
ently associated to microtubular filaments. Scale bar is 4 μm. Images were collected 24 hours after 
transfection at 37°C, 5% CO2. 
 
In Figure 23, microtubular ramifications and MTOC are clearly shown (see arrows in 
Figure 23). In Figure 23, the point of convergence of the perinuclear Gag dots, lo-
cated on the MTOC and the concomitant Gag association to the microtubular fila-
ments in different intracellular areas can be identified (see arrows in Figure 23). 
However, since the movement direction of the endo-lysosomal vesicles is one of the 
parameters that can identify the fate of a LE or LY, a time scanning imaging of a 
COS-7 cell co-transfected with Gag-mCherry and Tau-YFP was performed (Figure 
24). In the different time frames reported in this figure, it is possible to identify two 
Gag dots that, following a trajectory on the microtubular filaments, move away 
from the MTOC, suggesting that such vesicles might be associated to kinesin motor 
proteins. 
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Figure 24. Gag dots move on the microtubular filaments. COS-7 cell co-transfected with Gag-
mCherry (red channel) and Tau-YFP (green channel). The light blue arrows follow the movement of two 
Gag dots on the microtubular filaments. Frame times are indicated. Scale bar is 6 μm. Images were 
collected 24 hours after transfection at 37°C, 5% CO2. 
Gag- m Cherry
Tau-YFP
MTOC PM
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3.1.6 TBHQ-induced lysosomal calcium leakage causes fusion be-
tween Fluo5F containing compartments and enhanced re-
lease of VLPs 
 
The previously observed enlargement in Fluo5F-positive compartments after 
induced calcium-leakage with TBHQ (Figure 20), which de facto in HeLa cells corre-
sponded to an increased fluorescence intensity of the Fluo5F-positive vesicles and 
therefore to an increased lumenal calcium concentration, seems to be contradictory. 
However, enlargement of endo-lyososmal compartments after calcium release from 
the lysosomal lumen is a well-known consequence of a mechanism that involves 
fusion between LEs and LYs [112]. This mechanism can be physiologically activated 
by the binding of Nicotinic acid adenine dinucleotide phosphate (NAADP) to the ly-
sosomal two-pore channel (TPC), which in turn allows release of calcium from the 
LYs [121,122]. The fusion process between LEs and LYs is a calcium-mediated pro-
cess and a highly regulated mechanism that requires the co-operation of proteins of 
the SNAREs8_complex machinery [102], and might take place in response to very 
specific intracellular stimuli [121,122]. This fusion process usually entails mixing of 
the LEs/LYs content, which in this case may be in part represented by completely of 
partially formed VLPs. Besides such fusion processes, enhanced calcium concentra-
tions can activate exocytosis of LYs, that can fuse with the PM in a Synaptotagmin 
VII (Syt-VII) mediated manner [102,123]. Syt-VII is a protein localized on the 
membrane of LYs, able to mediate lipid-bilayer fusion if activated upon binding by 
calcium ions. Figure 25 shows a COS-7 cell transfected with Gag-CFP, stained with 
Fluo5F and Lysotracker and treated for 3 hours with TBHQ. As already shown in 
HeLa cells, an enlargement of the endo-lysosomal compartments (i.e. Fluo5F and 
Lysotracker positive vesicles) takes place (Figure 25A merged image). Specifically, 
considered that Lysotracker staining is specific only for LYs and Fluo5F most proba-
bly unspecifically stains LEs and LYs, events that mostly resemble pre- and post-
fusions between endo-lysosomal vesicles can be observed (see zoomed sections 
and schematic representations in Figure 25B).  The presence of Gag into the fused 
vesicles can be deduced by the CFP signal overlapping with the signal of Lysotracker 
and Fluo5F (zoomed section “2” in Figure 25B). 
 
                                          
8 (SNARE) Soluble N-ethylmaleimide-sensitive factor- attachment protein receptor.  
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Figure 25. TBHQ treatment induces fusion between LE and LY. (A) COS-7 cell transfected with 
Gag-CFP (light blue channel) and stained with 3 μM Fluo5F (green channel) and Lysotracker (red chan-
nel).  24 hours after transfection the cells were treated with TBHQ for 3 hours. The squares in the 
merged image indicate regions reported enlarged in (B). (B) Enlargements of 5 different sections of the 
merged image in (A); schematic representations of the visualized vesicles are also shown: the color-
code used in the schematic representation is the same of the fluorescent channels. Scale bar is 5 μm. 
Images were collected 24 hours after transfection at 37°C, 5% CO2. 
 
Notably, by comparing untreated and TBHQ-treated cells (Figure 26) the intracellu-
lar distribution of the enlarged Fluo5F compartments is changed upon lysosomal 
calcium leakage. Fluo5F vesicles are, upon TBHQ treatment, not anymore concen-
trated only in the perinuclear area, but rather more spread in the cytosol and local-
ized in perimembrane areas. The re-distribution of LYs upon TBHQ-treatment can be 
observed in Figure 27, where COS-7 cells transfected with a CFP-tagged version of 
the lysosomal protein Syt-VII are shown. Increased cytosolic concentration partially 
re-localize Syt-VII-positive vesicles (i.e. LYs) from the perinuclear area to the prox-
imity of the PM.  
 
0#13*21,""'1!311'-,





75C@3'$B@3/B;3<B7<2C13A7<B@/13::C:/@@327AB@70CB7=<=4:C=GA=B@/193@>=A7B7D3
1=;>/@B;3<BA!-1>@GGNOM<INA@>O@?RDOC%<B!$.GDBCO=GP@>C<II@G<I?NO<DI@?RDOC+$GPJ$
BM@@I >C<II@G <I?+*TNJOM<>F@M M@? >C<II@G CJPMN <AO@M OM<INA@>ODJI OC@ >@GGNR@M@ 
PIOM@<O@?JM   OM@<O@?RDOC2 &/ AJMCJPMN 2C@<M@< >JQ@M@?=T OC@ $GPJ$*TNJOM<>F@MKJNDODQ@
>JHK<MOH@IONDNDI?D><O@?=TRCDO@=JPI?<MD@N1><G@=<MDNH'H<B@NR@M@>JGG@>O@?<O]!
!-


75C@3+A&GB)#>=A7B7D31=;>/@B;3<BA@3:=1/B37<B63>@=F7;7BG=4B63# C>=<
'$B@3/B;3<B!-1>@GGOM<INA@>O@?RDOC1TO4''!$.GDBCO=GP@>C<II@GCJPMN<AO@MOM<IN
A@>ODJIOC@>@GGNR@M@PIOM@<O@?JM OM@<O@?RDOC2 &/AJMCJPMN!@GG=JPI?<MD@N<M@NCJRIDI
RCDO@>@GGIP>G@D<M@H<MF@?RDOC?JOO@?>DM>G@N1><G@=<MDNH'H<B@NR@M@<O]!!-

'I <??DODJI DI $DBPM@  < !-1 OM<INA@>O@? RDOC 1TO4'' <I? NO<DI@? RDOC
*TNJOM<>F@M <I? $GPJ$ PKJI 2 &/ OM@<OH@IO DN NCJRI $PNDJI KMJ>@NN@N JA *7N
RDOC*#N><I=@<B<DIQDNP<GDU@?=T OC@JQ@MG<KJA OC@ M@?RDOC OC@BM@@INDBI<GN
<I?OC@>JI>JHDO<IO@IG<MB@H@IOJANP>C>JHK<MOH@ION$PMOC@MHJM@?P@OJOC@
GTNJNJH<GNDU@DI>M@<N@1TO4''><I=@QDNP<GDU@?<N<MDIBGDF@NOMP>OPM@OC@M@=T
 
 
RESULTS AND DISCUSSION 
 
 
61 
identifying the lysosomal membrane (square sections in Figure 28). In the same 
image, the arrow indicates a group of LYs localized at the very proximity of the PM.  
   
 
Figure 28. Upon TBHQ treatment, LYs increase their size and migrate to the PM. COS-7 cell 
transfected with Syt-VII-CFP (light blue channel) and stained with 3 μM Fluo5F (green channel) and 
Lysotracker (red channel).  24 hours after transfection the cells were treated with TBHQ for 3 hours. The 
circle indicates the MTOC region where the LEs/LYs fusion events occur; the arrow indicates LYs docked 
at the PM; squares in the merged image visualize the typical ring-like structures of enlarged LYs. Scale 
bar is 5 μm. Images were collected at 37°C, 5% CO2. 
 
Furthermore, treatment of COS-7 with TBHQ for 3 hours, 48 hours after transfec-
tion with Gag-EGFP, resulted in an enhanced release of VLPs (Figure 29A), while 
knocking-down of the Syt-VII gene with siRNAs resulted in a decreased release 
(Figure 29C). 
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Figure 29. TBHQ treatment enhances release of VLPs, while Syt-VII siRNA diminishes it. (A) 
Quantification of VLPs release from COS-7 cells 48 hours after transfection with Gag-EGFP and treated or 
not for 3 hours with TBHQ. Error bars represent standard deviations of 3 independent replicates. (B) 
Western blot of purified VLPs from untreated (control) and TBHQ treated (+TBHQ) COS-7 cells, visual-
ized after staining with an anti-p24 antibody. 
 
3.1.7 Summary and conclusion  
 
This section described how Gag is distributed in the intracellular environment 
revealing a similar pattern in the two different cell types analyzed (i.e. HeLa and 
COS-7 cells).  Gag is found at the PM, in a dot-like form in the perinuclear area, 
and can be also observed in a diffuse distribution in the cytosol (Figure 13, Figure 
16 and Figure 21). It was shown that the intracellular dots are membrane-delimited 
compartments (i.e. vesicles) that belong to the endo-lysosomal system (Figure 19), 
enriched in intralumenal calcium and containing VLPs (Figure 17). Analysis of Gag’s 
intracellular localization in dependence of time in COS-7 cells (Figure 22) revealed 
that Gag can reach its endo-lysosomal localization in the perinuclear area very soon 
after its synthesis (considering the timing of blue-to-red switch of the FastFT, within 
the first 25 minutes), and the amount of Gag in this form as well its presence at the 
PM increase with time.  
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Figure 30. Schematic representation of the possible fates of the endo-lysosomal entrapped 
VLPs. Late endosomes (LEs) and lysosomes (LYs) that contain VLPs undergo different destinies (e.g. 
maturation and degradation, recycling). Upon release of calcium from LYs, LEs/LYs might fuse and LYs-
exocytosis occurs, allowing extracellular release of VLPs contained in such compartment. 
 
Calcium depletion from the lysosomal lumen resulted in an enhanced release of 
VLPs in COS-7 (Figure 29A) and in an unexpected release of VLPs in non-permissive 
HeLa cells (Figure 20), while Syt-VII knockdown resulted in a decreased release 
(Figure 29C). These observations can be converted into a model for the possible 
fates of the endo-lysosomal entrapped VLPs, reported in Figure 30: release of calci-
um from the lysosomal lumen, a process which physiologically takes place in re-
sponse to specific stimuli [121], induces fusion between LEs and LYs and, due to 
the increase of the cytosolic calcium level, exocytosis of LYs from the PM in a Syt-
VII mediated manner. Considering that VLPs are effectively contained in vesicles of  
the endo-lysosomal system, the model presented here suggests that LEs/LYs con-
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tent mixing and LYs fusion with the PM might represent a rescue mechanism of en-
do-lysosomal localized VLPs that were initially destined to degradation by the cellu-
lar machinery. In Table 2, the results and their respective interpretations presented 
in the sections 3.1.4 and 3.1.6, that allowed the identification of the suggested 
model (Figure 30), are summarized.  
 
 
Table 2. Summary of the results and conclusion from the sections 3.1.4 and 3.1.6. In green are 
highlighted the results concerning the characterization of the organelles involved in the suggested mech-
anism (see Figure 30). In blue and orange are highlighted the results related to TBHQ treatment and the 
Syt-VII knockdown, respectively. 
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3.1.8 DISCUSSION: intracellular routes of Gag and release of 
VLPs via calcium-mediated fusion between LEs/LYs and LYs 
exocytosis 
 
3.1.8.1 Gag’s intracellular routes to VLPs release: one mechanism for 
all cell-types? 
 
HIV-1 Gag, as other retroviral Gag proteins, is an N-myristylated membrane-
bound polyprotein, necessary and sufficient for production and release of VLPs. Af-
ter its synthesis in the free ribosomes in the cytosol, Gag traffics through the cell 
and reaches the site of particle production. Possible destinations of Gag have been 
suggested to include not only the PM, but also some membrane-limited intracellular 
compartments (e.g. LE/MVBs) [2,23]. However, the routes followed by Gag from its 
synthesis to the site of viral assembly still have to be completely characterized. 
Clearly, assembly at the PM may ensure efficient virus release and dissemination. 
On the other hand, the fact that the different viral components have to travel 
through the extremely compartmentalized cytoplasmic space to target the PM may 
represent an obstacle for a successful viral production. Free Gag and Gag assem-
bled as VLPs, or in form of immature virions, have been observed in intracellular 
compartments enriched in late-endosomal markers [2,23,30]. Furthermore, in pre-
vious study, Gag was shown first diffusely distributed in the cytosol, accumulates in 
perinuclear cluster, pass transiently through a MVB-like compartment, and then 
travel to the PM. Sequential passage of Gag through these temporal intermediates 
was confirmed by live cell imaging [2]. These observations suggested that Gag 
might be targeted also to endosomal membranes for assembly and budding into the 
lumen of LE/MVBs and subsequently exit the cell via an exosome release pathway. 
Furthermore, Gag’s use of proteins belonging to the ESCRT machinery, which facili-
tates budding of vesicles into the endosomal lumen, has been exhaustive demon-
strated [124,125].  
Nevertheless, perturbing LE/MVBs trafficking was shown to affect neither Gag asso-
ciation with the PM nor virus release. Moreover, in a study on HeLa cells, with the 
help of TIRFM to monitor the dynamics of single HIV-1 assembly events at the PM, 
it was shown that the Gag population that effectively participates on HIV-1 produc-
tion and budding is recruited directly from the cytosol and is of non-endosomal 
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origin, whereas those Gag assemblies that are not destined to be released as cell-
free virus are associated with LE markers and appeared to have been internalized 
via endocytosis [126]. Such controversial observations appear to further confuse 
the already unclear understanding of Gag’s trafficking and assembly processes. 
However, it has to be mentioned, that many of the studies that until now have fo-
cused on the understanding of Gag’s trafficking attempted to address this issue 
using non-authentic Gag derivatives, codon-optimized for higher expression in 
mammalian cells, and tagged with fluorescent proteins exhibiting slow maturation 
kinetics and non-physiological tissue culture cell lines (e.g. HeLa, COS, and HEK-
293T) [6]. Such experimental set-up (in particular concerning the use of the men-
tioned cell lines), on the other hand, allows easy transfection procedures and is 
particularly suitable for confocal microscopy. Not surprisingly, the use of different 
cell types (physiological and non-physiological) and different Gag expression sys-
tems in some cases led to contradictory results [6]. Nevertheless, many previous 
works on Gag trafficking and VLPs assembly conducted on HeLa, COS and HEK-
293T cells have demonstrated the validity and the relevance of such cell lines as 
models for the study of the cell-biology of Gag and other HIV-1 proteins 
[1,2,23,103,127]. Furthermore, the direct visualization of genetically unmodified 
HIV-1 proteins still remains elusive [103]. Only the recent development of fluores-
cent intracellular single domain nanobodies (i.e. chromobodies), the use of which 
was not applied in this study, offers a general approach for dynamic detection and 
visualization of virtually any natural and genetically unmodified factor in living cells 
[103,128].  
HIV-1 assembly site(s) in physiologically relevant cell types like macrophages and 
T-cells have also produced contradicting observations: although HIV-1 assembly 
and release in T-cells is now generally accepted as being PM-associated, in a recent 
study it was shown that LE/MVBs compartments in both T-cells and macrophages 
can support productive HIV-1 assembly; specifically, a MVB-targeted Gag mutant 
was released efficiently in these two cell types [23]. In macrophages it was shown 
that a significant proportion of HIV-1 assembly took place in intracellular compart-
ments with LE/MVBs markers [18], which in turn were shown to be present in the 
membranes of the released viruses. Interestingly, such intracellular compartments, 
marked with LE/MVBs proteins, are connected to the PM via micro-channels with a 
diameter of ca. 20 nm and therefore are actually deep invaginations of the macro-
phage PM [129]. It seems to be difficult to find a common mechanism for Gag’s 
trafficking in different cell types. Nevertheless, taking together the already men-
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tioned observations and considering the results from previous studies, Gag’s locali-
zation and release in physiologically relevant cell can be summarized as follows: 
Gag is primarily localized at the PM at steady state in T-cells [17]. In these cells, 
Gag is targeted to the PM with no prior interaction with MVBs. Subsequently, specif-
ic Gag’s interactions recruit the ESCRT machinery to the PM. On the contrary, in 
macrophages and DCs, multivesicular late endosome-derived compartments are the 
sites for Gag localization and particle production. In some cases, a regulated exocy-
tosis of the virus located in LE/MVBs takes place [6,62]. 
In conclusion, Gag's routes to VLPs assembly and release are different for different 
cell-types. Gag targeting to PM and VLPs assembly (upon transfection or viral infec-
tion) involve, in different cell-lines, trafficking through specific host-cell compart-
ment and the association to diverse host-cell structures.  
 
3.1.8.2 VLPs in intracellular compartments probably originate from the 
PM 
 
In this work, the distribution of Gag in the intracellular environment in two dif-
ferent cell types (e.g. HeLa and COS-7 cells) was studied. 24 hours after transfec-
tion, Gag was found in three different localization patterns: I) at the PM, II) in a 
dots-form in the perinuclear area, and III) in a diffuse state in the cytosol (Figure 
13, Figure 16 and Figure 21). Live cell confocal microscopy was applied to study the 
timing of intracellular Gag localization in COS-7 cells transfected with Gag tagged 
with FTs, that change their fluorescence from blue to red over time (Figure 22). 
These fluorophores allow identifying the intracellular localization of Gag populations 
that are present at different time points after Gag's synthesis. For example, the 
maximum fluorescence emission of the blue form of Gag-FastFT is reached 0.25 
hour (see Table 1 in Material and Methods section) after protein synthesis and sub-
sequently loses its fluorescence intensity, while the red form turns up. Therefore, 
the blue signal visualized by this fluorophore identifies Gag proteins that are at 
most 15 minutes "old". For the blue form of the MediumFT, the maximum fluores-
cence emission is reached after 1.2 hour. Both red forms of the two fluorophores 
are maintaining their fluorescence intensities for longer time, allowing the identifi-
cation of Gag populations that are present at least since 7.1 and 3.9 hours after 
synthesis, for the FastFT and the MediumFT, respectively.  
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COS-7 cells transfected with Gag-FastFT (Figure 22A) showed a blue Gag popula-
tion mostly enriched in dots in the perinuclear area and rarely localized at the PM, 
while the red form was found to be equally distributed in dots in the perinuclear 
region, homogeneously distributed in the cytosol and near to- or associated to the 
PM. Cells transfected with Gag-MediumFT (Figure 22B) mostly resembled the Gag-
FastFT transfected cells with the exception of the higher amount of red population 
of perinuclear dots. These results are summarized in Figure 31.  
 
 
Figure 31. Gag's presence at both the PM and in intracellular dots increases with time, reach-
ing equilibrium. Summary of the results shown in fig. 22. (A) Approximate amount of Gag at the PM or 
in the dots-form at different time points. The quantity of Gag at these sites is arbitrary indicated as "very 
low", "low", "high" and "very high". (B) On the basis of such classification, the amount of Gag at the PM 
(dark grey) and in intracellular dots (light grey) are depicted in function of the time after Gag's synthe-
sis. 
 
In particular, it can be noted that I) presence of Gag at the PM increases with time 
after protein synthesis and II) the earliest intracellular localization observed (blue 
form of Gag-FastFT) is the dot-like distribution in the perinuclear area, suggesting 
that Gag might be immediately targeted to intracellular compartments after synthe-
sis. However, Gag has been observed to bind membrane within 5–10 minutes post-
synthesis [37]. Specifically, it has been shown that Gag reaches the PM already 7 
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minutes after its synthesis, and can complete a budding within 20 minutes (see 
schematic representation in Figure 32).  
 
 
Figure 32. Schematic representation of the sequential steps in the assembly of HIV-1 at the 
PM. Gag assembly at the PM is shown divided in different assembly steps. In purple are indicated the 
times of the relative steps according to [37]. 
 
Hence, identification of virus assembly sites must account for the events that occur 
within this narrow window of time. Therefore, taking into account that the peak of 
maximum excitation for the blue form of the FasFT is reached 15 minutes after pro-
tein folding (0.25 hour), the blue dots of Gag-FastFT found in the perinuclear area 
can not be exclusively considered as the first localization site reached by Gag in 
COS-7 cells.  
In conclusion, most probably, also accordingly to previous observations [130], the 
population of Gag observed in such intracellular and perinuclear compartments is 
the result of a re-endocytosis of budding VLPs at the PM. The presence of complete-
ly or partially formed VLPs in intracellular compartments was confirmed by electron 
microscopy on HeLa cells (Figure 17) and on COS-7 (data not shown). 
 
3.1.8.3 Characterization of VLPs-containing intracellular compartments 
 
The intracellular distribution of Gag in perinuclear dots mostly resembles the 
localization of LEs and LYs. Specifically, with confocal and electron microscopy, it 
was shown that the intracellular dots are actually membrane-delimited compart-
ments that belong to the endo-lysosomal system (Figure 19). In addition, they co-
localized with either the lysosomal marker Lysotracker, or with the late endosomal 
protein Rab7 (i.e. Rab7-GFP), which was co-transfected together with Gag-CFP. Fur-
Exterior
PM
2 to 7 minutes 4 to 20 minutes   
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thermore, such Gag-containing intracellular vesicles move on the filaments of the 
microtubular system following trajectories advancing from the MTOC to the PM 
(Figure 23 and Figure 24). The host cell cytoskeleton, comprised of microtubules 
and actin filaments, has long been suggested of being involved in targeting viral 
proteins to particle assembly sites [131,132]. Microtubules mediate long-range car-
go transport and therefore are potentially suited for delivering viral proteins to as-
sembly sites like the PM, where actin filaments, which transport cargo across short 
distances, may play a role in virus budding and release. Recent findings suggest 
that inhibition of actin and tubulin remodeling in T-cells disrupts Gag and Env en-
richment at polarized raft-like membrane domains, Env incorporation into viruses, 
Gag release, viral infectivity, and cell-cell spread [6,133]. Conversely, Gag expres-
sion has been reported to remodel the actin cytoskeleton at the site of particle bud-
ding [17]. Two types of microtubule-based proteins with opposing motor activities 
exist; kinesins facilitate cargo transport toward the cell periphery, whereas dyneins 
promote cargo transport toward the perinuclear MTOC. Previous observations 
showed that the kinesin superfamily member KIF4 binds HIV-1 Gag [134], pro-
motes Gag trafficking to the PM, and perturbing KIF4 function reportedly diminishes 
virus production. 
In this work, the use of the low-affinity calcium fluorophore Fluo5F on Gag-
transfected cells resulted in the staining of intracellular compartments, which most-
ly co-localized with Gag-CFP (Figure 16). In fact, endosomal and lysosomal vesicles 
share the common characteristic to posses a high intralumenal calcium concentra-
tion, estimated to be between 500 and 600 μM [102,108,135]. LEs and LYs have 
also a high intralumenal concentration of other ions (e.g. chlorine and potassium) 
(see schematic representation in Figure 33) [136]. The presence of Fluo5F in other 
calcium-containing compartments (e.g. ER, mitochondria) could be excluded by 
confocal microscopy (Figure 18). Within the endo-lysosomal system, calcium is im-
portant for maintaining normal trafficking, recycling and vesicular fusion events 
[109]. Specifically concerning LYs, which are organelles primarily involved in degra-
dation and recycling processes, the remarkable presence of intralumenal calcium is 
related to the role of LYs in many cellular processes, not directly referred to the 
degradation processes of cellular components, but rather e.g. to calcium-mediated 
fusion between intracellular membranes and amplification of calcium signaling 
[109]. For instance, LYs are the target of one of the most potent intracellular calci-
um releasing second messengers: NAADP. This molecule directly interacts with ly-
sosomal TPC proteins and causes release of calcium from the lysosomal lumen, 
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contributing to the regulation of crucial cellular signaling processes important for 
diverse cellular functions (e.g. vesicles exocytosis, fertilization, cell death 
[115,121,137]). Endocytosis of calcium has been shown to contribute for only ca. 
50 μM to the total content of lysosomal calcium [138]. To reach higher intralumenal 
calcium concentrations, LYs use the activity of both a calcium transporter (i.e. a 
SERCA-ATPase), and a calcium/proton channel, which exploits the proton gradient 
across the LY membrane to import calcium ions into the lumen (Figure 20B).  
 
 
Figure 33. Schematic representation of the concentrations of ions inside the vesicles of the 
endo-lysosomal system during their maturation process. Concentrations of different intralumenal 
ions are reported in correspondence to the maturation state of the vesicles. Adapted from [136]. 
 
The passage of endocytosed material and membrane-bound proteins through the 
endocytic pathway of mammalian cells to LYs occurs via early endosomes (EEs) and 
LEs [102,138]. Direct fusion events between LEs and LYs represent de facto the 
main cargo-delivery mechanism to LYs. This content mixing can be a result of kiss-
and-run events [112] and/or direct fusion between the two organelles [113]. The 
luminal ionic composition of vesicles of the endocytic machinery is of considerable 
importance both in the trafficking of endocytosed ligands and in the membrane fu-
sion processes. In mammalian cells, the organelles of the late endosomal pathway 
have been shown to interact with each other and to be in dynamic equilibrium both 
in vivo and in vitro [102,108,139]. LYs are also involved in a secretory pathway 
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known as lysosomal exocytosis, which requires two sequential steps: I) recruitment 
of LY to the close proximity of the PM, II) fusion of the pool of pre-docked LYs with 
the PM in response to calcium elevation [113]. Lysosomal exocytosis plays a major 
role in several physiological processes such as cellular immune response, bone re-
sorption, and PM repair. Calcium-dependent lysosomal exocytosis was considered to 
be limited to specialized secretory cells; however, recent studies indicate that this 
process occurs many different cell types [102,113,137].  
HIV-1 VLPs (or HIV-1 virions) are found in LEs and LYs in almost all cell types and 
at different time points after infection or transfection with a Gag plasmid. Given the 
degradative nature of the LYs, the presence of VLPs in such compartments has been 
considered by previous studies not relevant for virus release, but rather connected 
to unproductive pathways, that more probably are destined to degradation [126]. 
Nevertheless, increased intracellular calcium concentration, similar to those reached 
during activation of calcium release upon specific physiological stimuli, was shown 
to enhance VLPs release in different cell types. It therefore was postulated that 
LE/MVBs-entrapped VLPs might be released due to a calcium-mediated vesi-
cles/vesicles and vesicles/PM fusion process.   
 
3.1.8.4 PLCǃ as host factor needed for efficient Gag targeting to PM 
 
The sources of intracellular calcium that are needed for the functionality of the 
various signaling pathways and for calcium-mediated mechanisms, as in the case of 
LYs-exocytosis, might be different (e.g. ER, mitochondria, LEs/LYs). Generally, vi-
ruses have evolved the capability to hijack the host cell machinery in order to 
achieve their own purposes. Calcium, in particular, was identified to play a role in 
almost every step in virus replication cycles [140]. Specifically in the case of HIV-1, 
the Tat protein has been shown to up-regulate viral gene expression and replication 
[141,142], allowing HIV-1 to replicate in inactivated T-cells [140]. Furthermore, 
Tat-induced disregulation of intracellular calcium levels leads to neurotoxicity and 
contributes to HIV-related dementia and further stimulates production of the pro-
inflammation cytokine TNF-Į, which plays a major role in progression to AIDS.  
One of the most relevant calcium stores in the cell is the ER. Activation of calcium 
release from this organelle usually is triggered by specific signals [109,143]. The 
signal cascade starts typically at a PM, upon activation of GPCR or TKR. The direct 
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release of VLPs. In this work, it was shown how an analog intracellular mislocaliza-
tion of Gag was obtained blocking the activity of only the Gq-protein-stimulated 
PLCǃ, with the use of the Gq-protein inhibitor Mepyramine (see schematic represen-
tation in Figure 34). These data suggest that a proper function of PLCǃ signaling 
pathway is essential for Gag targeting to PM and VLPs release. The reasons for this 
still have to be determined.  
 
3.1.8.5 LY/LE-entrapped VLPs can be rescued from lysosomal degrada-
tion through release from the host cell via calcium-mediated fu-
sion between LYs and LEs and lysosomal exocytosis 
 
Restoration of PM integrity after injury is essential for the survival of animal 
cells. As already mentioned, in many cell types LYs can fuse with the PM in re-
sponse to an increase in the concentration of cytosolic calcium. Such LYs provide 
the extra lipid bilayer for PM wound repair [111]. Calcium-regulated exocytosis of 
LYs and direct fusion with the PM require the activity of the ubiquitously expressed 
calcium-sensor, member of the synaptotagmin family, Syt-VII. When calcium is re-
leased from the lumen of LYs (e.g. upon stimulation via NAADP), a LEs/LYs fusion 
process might occur. Much of such fusions occur in the perinuclear region of the 
cell, since LEs and LYs are mostly concentrated near the MTOC. In common with 
other fusion events in the secretory and endocytic pathways, the fusion of LEs with 
LYs requires the presence of N-ethylmaleimide sensitive factor (NSF), soluble NSF 
attachment proteins (SNAPs) and a small GTPase of the Rab family, probably Rab7 
[102]. Similar to other fusion events, the fusion process between LYs and LEs can 
be divided into three fundamental steps: I) tethering, II) formation of a trans-
SNARE complex that bridges across the two organelles and III) membrane fusion 
[112,113] (see schematic representation in Figure 35).  
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3.2 HIV-VLPs phagocytosis in macrophages via ĮEnv-PS-
LUVs 
 
The aim of the second part of the work was to develop a nanotechnological sys-
tem able to induce phagocytosis of Gag/Env-VLPs (in the following part called HIV-
VLPs) in macrophages. An immunoliposomal system based on PS-containing lipo-
somes (ĮEnv-PS-LUVs) is here presented. Confocal microscopy imaging on live 
macrophages, electron microscopy and flow cytometry were applied to study the 
validity of the system (see schematic representation in Figure 37). 
 
 
Figure 37. Schematic representation of HIV-VLPs phagocytosed in the presence of ĮEnv-PS-
LUVs. ĮEnv-PS-LUVs bind to HIV-VLPs, are phagocytosed into macrophages (shown in grey) via a PS-
dependent mechanism and finally delivered to lysosomes. 
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3.2.1 ĮEnv-PS-LUVs trigger efficient phagocytosis of HIV-VLPs by 
macrophages 
 
The efficiency of phagocytosis of HIV-VLPs by macrophages in different condi-
tions was investigated. To this end, HIV-VLPs were produced co-expressing in HEK-
293T cells HIV-1 Gag-EGFP and Env, as already described elsewhere [47,144]. Puri-
fied HIV-VLPs were loaded on an SDS-Page and blotted to verify the presence of 
both Gag and Env proteins (Figure 38). As already mentioned before, it is known 
that the polyprotein Gag precursor, even in the absence of other viral proteins and 
the viral genome, is sufficient to drive the formation and the release of non-
infectious VLPs when expressed in an appropriate cell line. Furthermore, the pres-
ence of EGFP at the C-terminus of Gag, even if it decreases the yield of produced 
VLPs, affects neither the assembly nor the release process of VLPs [145] and repre-
sents a simple tracking strategy to monitor and quantify the presence of VLPs (e.g. 
when internalized by macrophages).  
 
 
Figure 38. Western blot of purified HIV-VLPs. HIV-VLPs were separated by electrophoresis through 
10% SDS-polyacrylamide gels and electroblotted onto nitrocellulose membrane. The presence of Gag-
EGFP and Env in the HIV-VLPs was determined with mouse anti-p24 (CA domain) and goat anti-gp120-
biotin conjugated antibodies. 
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Figure 39. Schematic representation of a ĮEnv-PS-LUV. The LUVs included in their bilayer phos-
phatidylserine (Phosphatidylserine polar head shown in red), biotinylated lipids (Biotin-cap of the lipid 
shown in grey) used to decorate the LUVs with biotin-conjugated ĮEnv-Abs (shown in green) via strep-
tavidin (shown in blue) binding, and thus obtained PS-containing LUVs bound to ĮEnv-Abs. 
 
100 nm radius PS-containing LUVs were produced. These LUVs included in their 
bilayer a biotinylated lipid used to decorate the LUVs with biotin-conjugated ĮEnv-
Abs via streptavidin binding, and thus obtaining PS-containing LUVs bound to ĮEnv-
Abs (ĮEnv-PS-LUVs) (see schematic representation in Figure 39). It was expected 
that the ĮEnv-PS-LUVs would effectively recognize and bind the Env proteins on the 
HIV-VLPs and, due to the presence of PS, would be phagocytosed by macrophages 
together with the bound HIV-VLPs (see schematic representation in Figure 37). For 
internalization measurements, HIV-VLPs were first mixed either with I) ĮEnv-PS-
LUVs, II) ĮEnv-LUVs (without PS), III) ĮEnv-Abs (i.e. antibodies without liposomes) 
or IV) PS-LUVs (i.e. PS-containing liposomes without antibodies). In the following 
step, they were administrated to macrophages and incubated by gentle agitation for 
1 hour at 37°C. The intracellular fluorescence signal of phagocytosed HIV-VLPs was 
quantified with flow cytometry. In the live cell confocal fluorescence microscopy 
images reported in Figure 40 it is possible to visualize the internalization of HIV-
VLPs/ĮEnv-PS-LUVs complexes in macrophages.  
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Figure 40. HIV-VLPs are most efficiently internalized in the presence of ĮEnv-PS-LUVs. Live 
cell confocal microscopy images of living macrophages incubated with HIV-VLPs together with ĮEnv-PS-
LUVs. The focal plane was positioned approximately at the middle of cell height. HIV-VLPs (green chan-
nel) co-localize with ĮEnv-PS-LUVs (magenta channel) in the intracellular environment. Scale bar is 2 
μm. Images were collected at 37°C. 
                                                                                                                     
The fluorescence images merged with the DIC channel in confocal-geometry give 
additional information about the localization of the HIV-VLPs/ĮEnv-PS-LUVs com-
plexes into the cells: visualization of part of the nuclear membrane, observable in 
the DIC channel, suggests that the internalized complexes are not localized on the 
cell surface, but rather in the inner part of the cells. Figure 41 further confirms that 
incorporation of PS into ĮEnv-LUVs resulted in the most effective phagocytosis of 
HIV-VLPs into macrophages. ĮEnv-LUVs or ĮEnv-Abs alone caused less internaliza-
tion of HIV-VLPs and the lowest internalization values were observed when viral 
particles were incubated by themselves or in the presence PS-LUVs without anti-
bodies. It appears clear that the internalization of the HIV-VLP/immunoliposome 
complex is determined primarily by the presence of the antibody-decorated lipo-
somes (PS-LUVs in particular), since HIV-VLPs are not internalized by themselves. 
For this reason, the attention was next focused on the mechanism of liposome up-
take by macrophages. Furthermore, since the presence of antibodies does not in-
crease the uptake efficiency induced by LUVs or PS-LUVs (data not shown), it was 
decided to use PS-LUVs and LUVs without ĮEnv-Abs for the following test.  
Merge Merge w ith DI C
ĮEnv- PS- LUVsHI V- VLPs
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Figure 41. Flow cytometry analysis show how ĮEnv-PS-LUVs trigger efficient internalization of 
HIV-VLPs. Macrophages were incubated for 1 hour at 37°C in gentle agitation with HIV-VLPs exclusively 
or together with ĮEnv-PS-LUVs, ĮEnv-LUVs, ĮEnv antibodies, or with PS-LUVs. (A) Representative flow 
cytometry histograms for all the examined samples. Each curve refers to a single independent meas-
urement for one treatment condition and represents the number of cells as a function of the fluorescence 
intensity of internalized HIV-VLPs. The color-code used for the histograms is the same used in panel B. 
(B) The fluorescence signal of internalized HIV-VLPs was quantified with flow cytometry and normalized 
to the value measured for the ĮEnv-PS-LUVs sample, averaged over a 10000-cell population. Error bars 
represent standard deviations of 6 independent replicates. The average fluorescence signal of ĮEnv-PS-
LUV samples was normalized to 100%. “*” corresponds to datasets that cannot be statistically distin-
guished (i.e. two-sample t-test probability p>0.05). “**” and “***” denote significantly different da-
tasets with two-sample t-test associated probability p<0.05 and p<0.01, respectively. 
 
The internalization efficiency of the liposomes under inhibition of actin polymeriza-
tion, which is known to be required for phagocytosis [146], was measured. Cyto-
chalasin D is a potent inhibitor of actin polymerization and a highly toxic compound 
for animal cells. To avoid an excessive toxicity of Cytochalasin D on macrophages, a 
concentration 10-fold lower than that usually needed to have 90% inhibition of 
phagocytosis was used [147]. Notwithstanding the very low amount of Cytochalasin 
D, these cells showed already ~30% less internalization of PS-LUVs (Figure 42A). 
Inhibition of dynamin-dependent processes (e.g. endocytosis) with the dynamin 
inhibitor Dynasore did not affect the internalization of the PS-LUVs (Figure 42B).  
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Figure 42. Inhibition of actin polymerization, and not of dynamin, decreases uptake of PS-
LUVs. Macrophages were incubated for 1 hour at 37°C with PS-LUVs or LUVs in the presence or in the 
absence of (A) 1 μM Cytochalasin D or of (B) 1 μM Dynasore. The fluorescence signal of internalized 
fluorescently labeled liposomes was quantified with flow cytometry and normalized to the value meas-
ured for the PS-LUVs sample, averaged over a 10000-cell population. Error bars represent standard 
deviations of 3 independent replicates. The respective value of ĮEnv-PS-LUVs was normalized to 100% in 
each experiment. “*” corresponds to datasets that cannot be statistically distinguished (i.e. two-sample 
t-test probability p>0.05). “***” denotes significantly different datasets with two-sample t-test associat-
ed probability p<0.05 and p<0.01, respectively. 
 
These results suggest that actin-mediated internalization pathways might play a 
prevalent role in the uptake of liposomes. Engulfment of external bodies through 
the phagocytosis process requires not only the polymerization of actin, but also the 
activation of a specific intracellular signaling [148]. Concerning phagocytosis of 
apoptotic cells, it was shown that an acute and sustained calcium flux from the ER 
into the cytosol of phagocytic cells represents a direct and specific consequence of 
the recognition of apoptotic bodies by macrophages [148]. In order to show wheth-
er the treatment of macrophages with the ĮEnv-PS-LUVs (but also with PS-LUVs - 
not shown) is able to trigger this specific intracellular response, the cells were load-
ed with the membrane-permeable calcium fluorophore Fura2, a fluorescent dye 
which binds to free intracellular calcium, and treated either with I) ĮEnv-PS-LUVs, 
II) ĮEnv-LUVs, or III) pretreated with Thapsigargin (Thaps) and then with ĮEnv-PS-
LUVs. Fura2 fluorescence can show an acute increase or decrease in its Àuores-
cence intensity reÀecting a change in the cytosolic calcium concentration. In Figure 
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43 the intracellular Fura2 fluorescence was visualized in a pseudo color mode and 
monitored live at an epifluorescence microscope. The addition of ĮEnv-PS-LUVs to 
macrophages resulted in a strong and fast increase of the intracellular Fura2 fluo-
rescence, while the addition of ĮEnv-LUVs did not. Furthermore, pre-treatment with 
Thaps, which causes the depletion of calcium from ER, and subsequent addition of 
ĮEnv-PS-LUVs did not result in an increase of the Fura2 fluorescence, suggesting 
that the intracellular source of calcium needed upon binding between macrophages 
and ĮEnv-PS-LUVs is the ER. 
 
 
Figure 43. Addition of ĮEnv-PS-LUVs to macrophages results in release of calcium from endo-
plasmic reticulum. Macrophages were incubated for 30 minutes at 37°C with Fura2-AM in calcium-free 
medium, then washed with PBS and, when indicated, treated with 2 μM Thapsigargin (Thaps) for 1 hour 
at 37°C. Addition of either ĮEnv-PS-LUVs or ĮEnv-LUVs was performed live at an epifluorescence micro-
scope. The pseudo color scale was the same for all the samples. Scale bar is 8 μm. 
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3.2.2 Internalization of PS-LUVs is specific for macrophages 
 
It was shown that cell type plays a prominent role in intracellular uptake of na-
noparticles with different physical characteristics [149,150]. In the context of our 
studies, it would be important to show that immunoliposomes are preferentially 
internalized by macrophages, rather than unspecifically interacting with the PM of 
also other cell types. To this end, the internalization of PS-LUVs in macrophages 
was compared with the internalization in epithelial non-phagocytic cells (e.g. Madin-
Darby canine kidney cells (MDCK)). The results shown in Figure 44 indicate that the 
uptake efficiency of PS- LUVs in this cell type is much lower (ca. 60% decrease) 
than in macrophages. This result is in agreement with previous studies showing 
increased internalization of negatively charged particles specifically to phagocytic 
cells [150]. 
 
 
Figure 44. Comparison of internalization efficiencies of PS-LUVs or LUVs in macrophages and 
MDCK cells. Macrophages or MDCK cells were incubated with PS-LUVs or LUVs for 1 hour at 37°C. The 
fluorescence signal of internalized fluorescently labeled liposomes was quantified with FACS and normal-
ized to the value measured for the PS-LUVs sample in macrophages, averaged over a 10000-cell popula-
tion. Error bars represent standard deviations of 3 independent replicates. The respective value of ĮEnv-
PS-LUVs was set to 100% in each experiment. “***” denotes significantly different datasets with two-
sample t-test (probability p<0.01). 
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3.2.3 The amount of PS in LUVs influences phagocytosis efficiency 
of both LUVs and HIV-VLPs 
 
Next, the effect of increasing PS concentration on the HIV-VLPs internalization effi-
ciency was investigated. The internalization of liposomes and HIV-VLPs is strongly 
correlated to the amount of PS incorporated in the liposome bilayer. As shown in 
Figure 45, this dependence is more pronounced for the liposomes (almost 10 fold 
increase in the internalization of ĮEnv-50mol%PS-LUVs compared to ĮEnv-
0mol%PS-LUVs) than for the HIV-VLPs. The highest internalization was observed 
for the HIV-VLPs sample incubated with ĮEnv-50mol%PS-LUVs. A lower but non-
negligible uptake of HIV-VLPs incubated with ĮEnv-0mol%PS-LUVs was also ob-
served, in agreement with the results reported in Figure 41. According to the re-
sults shown in Figure 45B, already 30mol% PS concentration in the ĮEnv-PS-LUVs 
is sufficient to induce significant HIV-VLPs internalization. Therefore, in all further 
experiments 30mol% PS concentration was used. In order to investigate the possi-
ble presence of multiple populations in our samples (e.g. cells that massively inter-
nalized liposomes coexisting with cells showing negligible internalization), the for-
ward scatter/fluorescence intensity dot-plot was analyzed. These 2-d histograms 
shown in Figure 45C-D report the cell distribution of two different samples of mac-
rophages as a function of cell-size and fluorescence intensity of internalized ĮEnv-
30mol%PS-LUVs. The dot-plots of untreated cells and cells incubated with ĮEnv-
30mol%PS-LUVs are shown in Figure 45C, respectively. First, the background fluo-
rescence of macrophages in an untreated sample was identified (population 1 -P1, 
rectangle in Figure 45C), i.e. the cells that did not internalize any liposome. Only 
few outliers were observed, and they were not included. The plot in Figure 45D re-
fers to cells that were incubated with ĮEnv-30mol%PS-LUVs. The vast majority of 
these cells can be grouped together as a single population (population 2 -P2, rec-
tangle in Figure 45D). Only a negligible amount of the total cell population shows a 
fluorescence signal compatible with the parameters identified in Figure 45C for P1. 
In other words, almost all of the macrophages incubated with ĮEnv-30mol%PS-
LUVs do internalize liposomes and the data here presented do not support the 
presence of heterogeneity in the examined samples. 
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Figure 45. Internalization efficiency of LUVs and HIV-VLPs is related to PS concentration. 
Macrophages were incubated for 1 hour at 37°C in gentle agitation with ĮEnv-PS-LUVs containing differ-
ent PS mol% concentration and HIV-VLPs.  The fluorescence signal of internalized fluorescently labeled 
liposomes (A) and HIV-VLPs (B) were quantified with flow cytometry and normalized to the value meas-
ured for ĮEnv-50mol%PS-LUVs, averaged over a 10000-cell population. Error bars represent standard 
deviations of 3 independent replicates. “*” corresponds to datasets that cannot be statistically distin-
guished (i.e. two-sample t-test probability p>0.05). “**” and “***” denote significantly different da-
tasets with two-sample t-test associated probability p<0.05 and p<0.01, respectively. (C-D) Representa-
tive dot-plots of two independent flow cytometry-measurements of 10000-cells populations. The two 
dot-plots report the distribution of the cells in relationship to their size (forward scatter) and fluores-
cence intensity of internalized ĮEnv-30mol%PS-LUVs. Panel C shows untreated cells identified as popula-
tion 1 (P1), and panel D shows cells incubated with ĮEnv-30mol%PS-LUVs and identified as population 2 
(P2). The previously determined P1 position in the graph is also shown in panel D. The cells distribution 
is reported as intensity profile of the number of cells (red= high, blue=low); outlier cells are indicated as 
single points. 
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3.2.4 ĮEnv-PS-LUVs deliver co-internalized HIV-VLPs to acidic 
compartments 
 
Once the ĮEnv-PS-LUVs-mediated phagocytosis of HIV-VLPs has been trig-
gered, it is of paramount importance that the internalized pathological agents are 
properly degraded. In order to investigate the exact intracellular fate of ĮEnv-PS-
LUVs and HIV-VLPs, confocal microscopy imaging of live macrophages incubated 
with ĮEnv-PS-LUVs and HIV-VLPs and stained with a marker for acidic compart-
ments was performed. The images in Figure 46A show that HIV-VLPs together with 
ĮEnv-PS-LUVs accumulate in lysosomes, while HIV-VLPs administrated alone to the 
macrophages (Figure 46B) do not localize therein. It is worth noting that, in the 
latter case, we observed a much lower internalization of HIV-VLPs, in line with the 
results shown in Figure 41. A statistical analysis of the intracellular localization of 
HIV-VLPs in 30 images of the three samples is shown in Figure 46C (see Material 
and Method section). This analysis revealed that more than 70% of the HIV-VLPs 
co-localize with LYs if they were together with ĮEnv-PS-LUVs. If the particles were 
administrated alone, the localization into LYs was estimated below ca. 14%. In the 
presence of ĮEnv-LUVs, the co-localization of HIV-VLPs into LYs was on average 
intermediate between the two above-mentioned cases. Also, although the ĮEnv-LUV 
samples were not statistically distinguishable from the ĮEnv-PS-LUV samples, they 
exhibited much larger sample-to-sample variation (see standard deviations in Fig-
ure 46C). In order to further characterize the intracellular localization of HIV-VLPs 
and immunoliposomes with high spatial resolution, a correlative fluorescence and 
electron microscopy imaging approach was used. Figure 47 shows that HIV-VLPs 
co-localize with ĮEnv-PS-LUVs in membrane-delimited intracellular compartments. 
These sub-cellular structures are vesicular in shape and well separated from the 
PM. 
 
RESULTS AND DISCUSSION 
 
 
89 
 
Figure 46. HIV-VLPs together with ĮEnv-PS-LUVs accumulate in LYs. Representative confocal 
images of living macrophages at 37°C stained with Lysotracker and treated with (A) HIV-VLPs together 
with the ĮEnv-PS-LUVs (green arrows indicate HIV-VLPs co-localized with ĮEnv-PS-LUVs into acidic com-
partments) or (B) HIV-VLPs alone for 1 hour at 37°C (yellow arrows indicate the HIV-VLPs outside acidic 
compartments). The fluorescence signals of internalized HIV-VLPs, ĮEnv-PS-LUVs and LYs marked with 
Lysotracker are shown. Cell boundaries are shown in white. White bars represent 2 μm. (C) Percentages 
of HIV-VLPs/LYs co-localization with or without co-administration of ĮEnv-PS-LUVs, or ĮEnv-LUVs. The 
co-localization was calculated as ratio between overlapping areas (i.e. pixels occupied both by HIV-VLPs 
and Lysotracker) and total pixel areas occupied by HIV-VLPs, expressed in percentage and averaged over 
ten different confocal micrographs. Standard deviation (SD) and two-sample t-test probability (compari-
son to ĮEnv-PS-LUV sample) are also shown. 
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Figure 47. HIV-VLPs together with ĮEnv-PS-LUVs accumulate in phagosome-like compart-
ments. Correlative fluorescence and electron microscopy. (A-E) HIV-VLPs (green) and ĮEnv-PS-LUVs 
(red) were visualized by confocal laser scanning microscopy and correspond to a membranous, phago-
some-like structure imaged by transmission electron microscopy (F). (A) Fluorescence confocal image, 
(B, E, F) electron micrographs, (C, D) correlation of fluorescence images with electron micrograph by 
alignment of cellular surface structures. Indicated squares represent the area of magnification in the 
subsequent panel. Scale bars: 5 μm (A-C), 1 μm (D,E), 500 nm (F). 
 
 
3.2.5 Treatment with HIV-VLPs and ĮEnv-PS-LUVs does not affect 
viability of macrophages 
 
Finally, the effects of HIV-VLPs/ĮEnv-PS-LUVs treatment on the viability of 
macrophages was tested. The cells were treated with HIV-VLPs/ĮEnv-PS-LUVs or 
10% dimethylsulfoxid (DMSO), and incubated for 1, 48 or 72 hours at 37°C. Sub-
sequently, two different tests were performed in parallel. The results of the first test 
are shown in Figure 48A, which reports the values of responsiveness of the cells to 
the CellTiter-Blue test. This test measures the metabolic activity of the cells upon 
addition of the non- fluorescent dye resazurin. During the incubation period, cells 
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convert resazurin to the fluorescent resorufin product. The conversion of resazurin 
to fluorescent resorufin, measured at a plate-reader, is proportional to the number 
of metabolically active and viable cells. As shown in Figure 48A the viability of the 
cells treated with HIV-VLPs/ĮEnv-PS-LUVs is not affected. Moreover, after 72 hours 
the curves of treated and untreated cells both increase, indicating that the cells are 
actively dividing. As expected, the metabolic activity of the DMSO (positive control) 
treated cells decreases monotonously over the observation time.  
 
 
Figure 48. Treatment with HIV-VLPs and ĮEnv-PS-LUVs does not affect viability of macro-
phages. (A) Macrophages were plated in 96-well plates and incubated with HIV-VLPs/ĮEnv-PS-LUVs or 
10%DMSO or with medium only, for the indicated times. The fluorescence signal of the converted reso-
furin product for each sample was quantified with a plate reader and normalized to the value measured 
for the “untreated cells 1 hour after treatment” sample. Error bars represent standard deviations of 24 
independent replicates. (B) Macrophages were plated in 12-well plates and incubated with HIV-
VLPs/ĮEnv-PS-LUVs or 10%DMSO or with medium only, for the indicated times. The fluorescence signal 
of propidium iodide for each sample was quantified with FACS analysis and normalized to the value 
measured for the “10% DMSO-treated cells 1 hour after treatment” sample. Error bars represent stand-
ard deviations of 3 independent replicates. 
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The second test performed was the propidium iodide (PI) test. PI is a fluorescent 
and intercalating agent, which shows an increase up to 30 fold of its fluorescence 
upon binding to nucleic acids. PI is membrane impermeable and generally excluded 
from viable cells. The fluorescence of PI was measured with FACS. As shown in Fig-
ure 48B, cells treated with HIV-VLPs/ĮEnv-PS-LUVs maintain low values of PI fluo-
rescence over 72 hours after addition of the particles/liposomes. For the positive 
control, a strong decrease of membrane impermeability is observed in the first 
hour. Concerning the results of the DMSO control on a longer time range (see 48-
hours and 72-hours points, marked in red), two aspects must be considered: first, 
treatment with 10% DMSO is known to produce almost 90% cell death after 1 hour 
treatment [151]. Second, the FACS measurements must be performed in PBS, 
which implicates that the dead cells detached and present in the culture medium 
were excluded from the FACS analysis. Therefore, the DMSO-treated cells after 48 
and 72 hours, which show low level of PI fluorescence, most probably are repre-
sentative only of the 10% of the survived cells after the first hour. 
 
3.2.6 Summary and conclusion 
 
The results shown in the previous section demonstrated the efficacy of ĮEnv-
PS-LUVs in triggering efficient internalization of HIV-VLPs in macrophages, without 
affecting cell viability. The efficient internalization of HIV-VLPs into macrophages 
was shown to be primarily dependent by I) the presence of PS into the LUVs and II) 
the decoration of the LUVs with ĮEnv-Abs (Figure 41). The mechanism of internali-
zation of the HIV-VLPs/immunoliposomes complex was identified as phagocytosis. 
In fact, inhibition experiments demonstrated the need of actin polymerization for 
successful internalization of HIV-VLPs in macrophages. Furthermore, the release of 
calcium from the ER in macrophages, which is necessary (and specific) for a suc-
cessful cargo-phagocytosis [148], occurred exclusively after addition of PS-LUVs 
and was not observable after depletion of the ER-calcium stores (Figure 43). In-
creasing amount of PS in the immunoliposomes correlated with higher internaliza-
tion of both liposomes and HIV-VLPs. Fluorescence confocal and electron microsco-
py of macrophages treated with HIV-VLPs and ĮEnv-PS-LUVs showed that HIV-VLPs 
are localized in membrane-delimited vesicles and that, specifically ĮEnv-PS-LUVs, 
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and not ĮEnv-LUVs, are able to deliver the viral particles to membrane-delimited 
phago-lysosomal compartments (see schematic representation in Figure 49). 
 
 
Figure 49. Representation of HIV-VLPs phagocytosed by a macrophage in the presence of 
ĮEnv-PS-LUVs. ĮEnv-PS-LUVs bind to HIV-VLPs, are phagocytosed into macrophages via a PS-
dependent mechanism and finally delivered to lysosomes. The presence of internalized HIV-VLPs and 
ĮEnv-PS-LUVs can be evaluated by fluorescence: HIV-VLPs are made by Env and Gag-EGFP (shown in 
green in the cartoon) and ĮEnv-PS-LUVs contain Vybrant DiI (shown in red in the cartoon). On the back-
ground, an electron micrograph of a macrophage treated with HIV-VLPs together with ĮEnv-PS-LUVs 
(taken from Figure 41). 
 
Now, at this point, it has to be highlighted that, even if the previously described 
mechanism for VLPs release from LYs (LYs exocytosis) might be shared also by 
macrophages, phagocytosis of HIV-VLPs and subsequent delivery to acidic com-
partments (i.e. LYs) via PS-immunoliposomes is expected to follow a very specific 
internalization pathway proper to the mechanism of clearance of apoptotic cells by 
macrophages. This process, initiated by PS recognition, is known to represent a 
highly degradative pathway, characterized by an immediate targeting of the cargo 
to phago-lysosomes that undergo a progressive acidification of the phagosomal 
lumen and acquisition of vacuolar H+-ATPases [129,152].  
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3.2.7 DISCUSSION: internalization of HIV-VLPs into macrophages 
via ĮEnv-PS-LUVs-mediated phagocytosis 
 
 Macrophages are believed to play a potential active role in the fight of the 
immune system against HIV-1. However, as soon as these cells are infected by the 
virus, many of their effector functions are impaired. This represents one of the prin-
cipal causes of the development of AIDS pathogenesis. Specifically, phagocytosis of 
opsonized viral particles is compromised in infected macrophages [66,67,153]. On 
the other hand, PS-dependent phagocytosis seems not to be affected by the pres-
ence of the virus [80]. Also, in those cases where phagocytosis of apoptotic cells 
seemed affected by HIV-1 infection, the molecular mechanisms involved are not 
related to specific PS-recognition [154-156]. In this study, efficient internalization 
of HIV-VLPs into macrophages via ĮEnv-PS-LUVs -mediated phagocytosis was 
demonstrated. 
 
3.2.7.1 Phagocytosis of HIV-VLPs via ĮEnv-PS-LUVs in macrophages 
 
The internalization of HIV-VLPs into macrophages via ĮEnv-PS-LUVs was highly 
efficient and much higher compared to the cases of incubation of HIV-VLPs with 
ĮEnv-LUVs, PS-LUVs or with antibodies alone. The intracellular localization (rather 
than simple binding to cell surface) of the HIV-VLPs/immunoliposomes complexes 
can be deduced by the data in Figure 40. As previously stated in the Results (sec-
tion 3.2.1), the confocal plane was positioned approximately in the middle of the 
cell plane, therefore excluding detection of liposomes or VLPs bound to the PM (well 
above or below the focal plane). PS-dependent internalization (rather than simple 
membrane binding) was already confirmed in the same system (i.e. PS-liposomes 
in macrophages) [94]. These results are compatible with a model according to 
which HIV-VLP bind to liposomes through a specific antibody. Subsequently, PS-
containing liposomes are phagocytosed due to the presence of PS, carrying the 
bound viral particles into the macrophage. In the absence of antibodies, PS-LUVs 
are efficiently internalized but cannot carry HIV-VLPs into the phagocyte (see e.g. 
Figure 41). Furthermore, the mere presence of ĮEnv-Abs bound to HIV-VLPs does 
not elicit phagocytosis by itself. This result is reasonable, since the antibody used 
here (goat ĮEnv IgG) should not be specifically recognized by mouse macrophages. 
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Therefore, this in vitro system mirrors in this respect the behavior of HIV-infected 
macrophages characterized by impaired antibody-dependent phagocytosis. 
 
3.2.7.2 Influence of PS amount in LUVs phagocytosis efficiency of both 
LUVs and HIV-VLPs  
 
The specific amount of PS strongly correlates with the internalization of lipo-
somes: LUVs made with 0 or 10 mol% PS have a similar degree of internalization 
and both are internalized to a much lesser degree than LUVs with 30-50 mol% PS. 
Qualitatively, these results are compatible with previous studies [94]. The amount 
of PS needed for optimal internalization in our experiments is somewhat different 
from that reported by Geelen et al. [94], probably due to e.g. differences in the cell 
line used, specific lipid composition, and/or liposome size. PS-mediated internaliza-
tion of the PS-LUVs must be ascribed to the previously characterized capability of 
PS-liposomes to activate a specific phagocytosis signal in macrophages [149]. The 
PM of viable cells is characterized by an asymmetric distribution of phospholipids 
across the bilayer, PS being mostly localized into the inner leaÀet of the PM. Expo-
sure of the anionic phospholipid PS in the outer leaflet represents one of the most 
dramatic changes on the surface of apoptotic cells [74,77], eventually leading to 
phagocytosis by macrophages in vivo. 
The dependence of HIV-VLPs uptake on the presence of PS in liposomes is less 
straightforward compared to uptake of the mere PS-liposomes, since this lipid is not 
strictly needed for HIV-VLPs internalization. In fact, a non-negligible internalization 
of HIV-VLPs in the presence of immunoliposomes without PS was observed. Alt-
hough these data do not provide a definitive explanation for this observation, one 
possibility could be that HIV-VLPs and ĮEnv-LUVs form large aggregates that are 
non-specifically internalized by macrophages. Such aggregates seem to be enriched 
in HIV-VLPs rather than lipids (see Figure 45A and 45B – noticeable internalization 
of HIV-VLPs compared to that of immunoliposomes in absence of PS). Furthermore, 
non-specific internalization of HIV-VLPs does not occur in the absence of immu-
noliposomes (Figure 41). Nevertheless, it must be emphasized that PS should be 
present in a rationally designed liposomal system for viral particle phagocytosis 
since I) the presence of at least 30 mol% PS dramatically increases internalization 
of HIV-VLPs and II) the presence of PS triggers an internalization pathway which is 
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specific and supposedly not impaired in HIV-infected macrophages. 
 
3.2.7.3 ĮEnv-PS-LUVs internalization: mechanism and target specificity 
 
Different receptors on the macrophage membrane are known to interact with 
ligands (e.g. PS) on the apoptotic cell surface, resulting in the association of dead 
cells to the macrophages, which represents the first step of phagocytosis [157]. 
The recruitment of specific receptors also triggers cytoskeletal changes in the phag-
ocytic cell structure required for the engulfment of apoptotic cells. Here, it was 
shown that inhibition of actin polymerization, and not of dynamin, correlates with a 
strong decrease in PS-LUVs uptake, suggesting that the mechanism of PS-LUVs 
internalization is indeed phagocytosis. In the context of a therapeutic approach 
against HIV-1, it is of great importance to ensure that the pathological agent (i.e. 
virus/immunoliposome complexes) is specifically delivered to the appropriate cell 
types where they can be properly disposed of, without toxic effects for the target 
cells. First it was verified that treatment with HIV-VLPs and ĮEnv-PS-LUVs is not 
toxic for macrophages (see Figure 48). Then it was investigated how specifically PS-
LUVs are taken up by macrophages, comparing the internalization of PS-LUVs in 
macrophages and Madin-Darby Canine Kidney cells (MDCK), here used as an ex-
ample of non-phagocytosing cells (see Figure 44). The results presented in this 
work show that MDCK cells internalize a significantly lower amount of PS-LUVs 
compared to macrophages. 
 
3.2.7.4 Intracellular fate of internalized HIV-VLPs 
 
After phagocytosis, depending on different factors (e.g. the intrinsic nature of 
the cargo, the type of the target cell, the internalization pathway), the internalized 
material is delivered to specific intracellular compartments. This will eventually de-
termine the fate of the acquired content [158]. Subcellular localization is extremely 
important in HIV-1 infection as well, as it influences also its ability to infect the host 
and other cells [159]. Indeed, HIV-1 particles found in membrane-proximal com-
partments with neutral pH in macrophages (e.g. viral containing compartments 
(VCCs) and endosomal-like structures) [129] are still infectious and represent the 
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so-called virus-reservoirs, known to be one of the major causes of viral persistence 
in the host [18,160]. VCCs, shown in Figure 50, are tubule-vesicular membranous 
webs that extend throughout the macrophage and are frequently connected to the 
extracellular space [129].  
 
 
Figure 50. Virus-containing compartment (VCC) morphology. (A–H) Digital slices (from electron 
tomography) through a region of a HIV-1-infected macrophage depicting the morphological complexity 
and variability of the VCC. The arrows point to membranous protrusions that were initially thought to be 
a separate form of VCC but were later shown to be part of the overall three-dimensional VCC structure. 
Scale bar corresponds to 200 nm. From [129]. 
 
Confocal microscopy live imaging and correlative electron microscopy of macro-
phages showed that HIV-VLPs bound to ĮEnv-PS-LUVs are localized into membrane-
delimited intracellular compartment morphologically similar to phagosomes and 
enriched in the LYs tracker Lysotracker. More specifically, image analysis (Figure 
46C) showed that immunoliposomes - with or without PS - induce delivery of HIV-
VLPs into LYs. This effect is significantly more reproducible in the presence of PS, as 
judged by the small standard deviation observed for the ĮEnv-PS-LUV sample 
(Figure 46C, compare to ĮEnv-LUVs). Lysotracker-stained compartments are very 
different from the above-mentioned VCCs, and are probably highly acidic vesicles. 
These results are in agreement with the fact that, as previous studies have shown, 
apoptotic cells, once inside the phagocyte, are processed via a phago-lysosomal 
pathway characterized by a progressive acidification of the phagosomal lumen and 
acquisition of vacuolar H+-ATPases [129,152]. 
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4 CONCLUSION AND OUTLOOK 
 
 
4.1 Identification of a calcium-dependent pathway for 
VLPs release as potential new antiviral target  
   
Although antiretroviral therapy effectively diminishes viral replication and sub-
stantially increases survival of patients, it has not been possible yet to achieve a 
cure. High viral replication rate, generation of extensive viral genetic diversity and 
spontaneous development of antiretroviral-drugs resistance (or interruption of an-
tiretroviral therapy) result in rebound of virus replication and development of AIDS 
[84]. Furthermore, HIV-1 is able to escape from the immune surveillance establish-
ing reservoirs in a small pool of latently infected cells. For all these reasons, re-
sistance to the antiretroviral drugs, and the emergence of drug-resistant viral 
strains may occur, resulting, in the end, in treatment failure. The demand of new 
antiretroviral drugs and innovative therapies is therefore not decreasing and still 
remains an important objective for the research. 
In recent years, medical and pharmaceutical research has supported, in contrast 
with conventional pathogen-targeting strategies, a new drug discovery paradigm 
[161]: it has been proposed that focusing on identifying and targeting the host fac-
tors hijacked by the pathogens might represent a novel possible successful strategy 
to develop new therapies. In other words, this kind of therapeutic approach against 
pathogens should not target molecular structures of the pathogen itself, but rather 
host structures or cellular mechanisms that directly or indirectly support one or 
more fundamental steps of the pathogen’s life cycle [162]. Examples of drugs that 
have host factors as targets are various, and in some cases already available for 
treatment (see Table 3).  
 
CONCLUSION AND OUTLOOK 
 
 
100 
 
Table 3. Examples of antiviral or antiparassitic drugs that inhibit cellular factors requested for 
the pathogen's life cycle. The information summarized in this table were taken from [161]. 
 
Concerning anti-HIV-1 therapy, the CCR5 co-receptor has been suggested to repre-
sent an attractive anti-HIV target, since individuals with a natural CCR5Ʃ32 muta-
tion (which has little apparent impact on immune status or general health) are 
highly protected against HIV-1 infection. Maraviroc (brand-named "Selzentry" 
or "Celsentri") is an antagonist of the CCR5 receptor, which inhibits the viral fusion 
process with the host PM [163]. This drug is commonly used in the therapy of AIDS 
patients.  
In the last few years, the study of the interactions between HIV-1 and the host cell 
and the characterization of the viral life cycle in its different steps have seen some 
progresses, specifically thank to the technical advancements (e.g. super resolution 
microscopy) and the use of RNAi screening procedures [6]. In particular, the central 
process of ESCRT mediated budding seems to be now fairly well established [124]. 
In particular, the cellular factors exploited by Gag to achieve the viral assembly pro-
cess include cellular structures, single proteins and protein complexes [164,165]. 
Such interactions between host and viral components may surely provide attractive 
new antiviral targets [84]. Nevertheless, identification of such host-directed targets 
requires a detailed biological and biochemical characterization. However, the differ-
ent aspects of viral life cycle, particularly regarding the release of viral particles, 
still require further investigations. Specifically, despite the progress achieved in un-
derstanding viral structural properties and its single components, high-resolution 
structures of their complexes with cellular partners are very limited. Moreover, the 
fact that the virus is exploiting different assembly pathways in different target cells 
represents a further obstacle in the identification of potential target for a new an-
tiretroviral therapy.  
Pathogen Host  factor hijacked Role played by the host  factor in the pathogen life  cycle Drug of choice
SARS-Coronavirus clathrin-dependent endocytosis machinery Entry into the host cell Chlorpromazine 
Hepat it is C virus Endoplasmic-reticulum glucosidase Folding of the envelop proteins Celgosivir 
Vaccinia virus Abl-kinase /Src-kinase Actin motility Gleevec 
Plasm odium  falciparum 20S proteasome Proteasome activity MLN-273
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In this work, on the basis of previous preliminary observations [1,2,23], an intra-
cellular pathway for viral release, which functions through the activity of cellular 
machineries common to all cell types was investigated. The here presented results 
allowed the identification of a model for a calcium-dependent release of VLPs which 
I) further confirms the relevance of intracellular calcium in the release of VLPs from 
the host cell, II) identifies a possible calcium-dependent pathway for rescue of 
LY/LE entrapped VLPs from degradation, which requests the activity of the lysoso-
mal protein Syt-VII. The slight modulation in VLPs release upon TBHQ-treatment or 
knockdown of Syt-VII suggests that the role played by this pathway, in the context 
of HIV-1 release from the infected cell, might be not predominant. However, chemi-
cal compounds that modulate the intracellular calcium signaling, only mimicking the 
activity of extracellular (or intracellular) stimuli, might not be able to exactly repro-
duce real physiological conditions. The intracellular concentration of calcium might 
undergo oscillations that vary in the intensity and duration in dependence of the 
activated pathway. Furthermore, considering that perturbation of host-cell PM is a 
primary mechanism of HIV-1 cytopathology [166], it is reasonable that the virus 
itself, also through the continuous budding at the PM, might be able to induce a 
mechanism of PM-repair that requires the activity of lysosomal calcium signaling 
and ends in LYs-exocytosis and consequent release of LYs-entrapped VLPs. 
The discovery of new cellular factors that play a role in the complex release mecha-
nism of HIV-1 should pave the way for further investigations and hopefully will lead 
to identification of novel mechanisms and/or pathways critical for virus assembly. 
Such knowledge should facilitate the development of better approaches for the 
treatment of HIV-1. 
 
4.2 Medical and biological relevance of the immunolipo-
somal system and further perspectives 
 
 Liposomes containing PS have been used in the past to target macrophages 
(e.g. for in vivo imaging [167]), and liposomes bound to antibodies have been 
largely used to target specific cells (e.g. during drug delivery [93,168]).  This work 
adds to the existing body of knowledge by joining these two unrelated approaches 
in order to address the problem of the poor immune response against HIV-1. This is 
the first study in which the above-mentioned strategies are combined to produce a 
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nanobiotechnological system able to elicit phagocytosis and delivery of HIV-VLPs to 
acidic compartments (i.e. LYs) in macrophages.  
 
Exploiting PS-mediated phagocytosis of HIV-1 particles would potentially help to 
support the immune system in the case of HIV-1 infection on multiple levels, with 
several potential advantages: first, the rapid clearance of HIV-1 particles from the 
circulation via macrophage-phagocytosis could diminish the high viral load observed 
in the first few months after the infection. Moreover, the direct delivery of the inter-
nalized particles to acidic compartments should allow for a more rapid destruction 
of the virus (Figure 46 and Figure 47). Second, PS-mediated phagocytosis of the 
viral particles, exploiting a specific cargo-internalization pathway different in re-
spect to that activated by opsonized antigens, would allow circumventing the im-
paired phagocytosis via the FcǄR pathway, which has been reported to be compro-
mised in infected patients [68,69]. Furthermore, the mere binding of anti-HIV IgG 
to viral particles may even favor the persistence of the virus if trapped by follicular 
dendritic cells (FDC): a study has shown that optimal maintenance of HIV-1 infec-
tivity requires both antibodies against particle-associated determinants and the 
FDC-FcǄR [169]. Third, the influence of PS modulating the inflammatory response 
in macrophages, already demonstrated in previous studies [167,170], would 
strongly decrease the ongoing activation of the immune system and persistent in-
flammation, both of which are key driving forces in the loss of CD4+ T-cells and pro-
gression to AIDS pathogenesis [41]. Specifically, in macrophages PS is able to 
down-regulate TNF-Į production [171], whose up-regulated production is connect-
ed to HIV-associated dementia and other neuronal injuries [59,142]. Fourth, PS-
mediated phagocytosis of apoptotic cells is known to induce antigen-presentation to 
the major histocompatibility complex class II on the macrophage surface [74,172]. 
Accidentally, a proper antigen presentation via major histocompatibility complex 
class II requires actin-dependent phagocytosis of the cargo [173], similarly to the 
internalization of the immunoliposomes described in this work. This may result in 
the stimulation of specific T-helper cells and, ultimately, stimulation of specific B-
cells, which results in the subsequent secretion of antibodies. In conclusion, beside 
the development of a vaccine for HIV-1, which still seems extraordinarily challeng-
ing, and the advances in the identification of potent neutralizing antibodies 
[174,175], the immunoliposomes investigated in this work might provide the basis 
for the design of new and alternative therapeutic applications to combat HIV-1 in-
CONCLUSION AND OUTLOOK 
 
 
103 
fection and positively stimulate the immune system.  
Although in this work the capability of ĮEnv-PS-LUVs to produce efficient HIV-VLPs 
phagocytosis by macrophages was demonstrated and the potential role of this 
nanobiotechnological approach stimulating the immune system against HIV-1 and 
reducing persistent inflammation was illustrated, additional experiments on the po-
tential of ĮEnv-PS-LUVs are required to further characterize the system presented 
here. For instance, proving ĮEnv-PS-LUVs functionality in other cells of the immune 
systems (e.g. DCs), testing the ĮEnv-PS-LUVs capability to also bind wild type  HIV-
1 virus, testing the usefulness of this system on other viruses, and in vivo studies 
represent future work that could be of great importance.
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Appendix 
 
Molecular structures of the lipids used in this work. 
Images from the website of Avanti Polar Lipids, Inc. 
 
L-Į-phosphatidylcholine  
 
 
1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-(cap-biotinyl) 
 
 
1-palmitoyl-2 (dipyrrometheneborondifluoride) undecanoyl-sn- glycero-3- phosphocholine  
 
 
1,2-diacyl-sn-glycero-3- phospho-L-serine 
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Abbreviations  
Abs 
AIDS 
ART 
AZT 
CA 
CTL 
DAG 
DC 
DIC 
DMSO 
Env 
ER 
ESCRT 
 
FACS 
FcJR 
FDC 
Gag 
GPCR 
HIV-1 
IgG 
IN 
LE 
LTR 
LUV 
LY 
MA 
MTOC 
MVB 
NSF 
NC 
PI 
Antibodies 
Acquiered immunodeficiency syndrome 
Anti-retroviral therapy 
Azidothymidine 
Capside 
Cytotoxic T-cell 
Diacylglycerol 
Dendritic cell 
Differential interference contrast (microscopy) 
Dimethyl sulfoxide 
Envelope 
Endoplasmic reticulum 
Endosomal sorting complexes  
required for transport 
Fluorescence-activated cell sorting 
Fc-gamma receptor 
Follicular dendritic cell 
G-antigen 
G-protein coupled receptor 
Human immunodeficiency virus-1 
Immunoglobulin G 
Integrase 
Late endosome 
Long terminal repeat 
Large unilamellar vesicles 
Lysosome 
Matrix 
Microtubule-organization center 
Multivesicular bodies 
N-ethylmaleimide-sensitive factor 
Nucleocapside 
Propidium iodide 
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PIP2 
PKC 
PLC 
PM 
Pol 
PR 
PS 
RES 
RF 
RT 
SD 
SERCA 
SIV 
SNAP 
SNARE 
Syt-VII 
TBHQ 
Thaps 
TKR 
TNF 
TPC 
TRIM5 
VCC 
VLP 
Phosphatidylinositol(4,5)-bisphosphate 
Protein-kinase C 
Phospholipase C 
Plasma membrane 
Polimarase 
Protease 
Phosphatidylserine 
Reticuloendotelial system 
Restriction factor 
Reverse transcriptase 
Standard deviation 
Sarco/endoplasmic reticulum Ca2+-ATPase 
Simian immunodeficiency virus 
Soluble NSF attachment protein 
SNAP receptor 
Synaptotagmin-VII 
Tert-butylhydroquinone 
Thapsigargin 
Tyrosine-kinase receptor 
Tumor necrosis factor 
Two pore channel 
Tripartite motif-containing motif 5 
Virus-containing compartment 
Virus-like particle 
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